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ABSTRACT 
Novel genetic engineering tools for functional alteration of mammalian gut microbiomes 
Sway P. Chen 
 
The gut microbiome is an integral component of the human body that plays a role in many 
physiological processes. Dysbiosis, an imbalance of the microbiome, has been associated with 
disease states including inflammatory bowel disease, type II diabetes, and obesity, and moreover, 
contributes to the pathogenesis of these states. Understanding the functional mechanisms 
governing microbial ecology and microbe-host interactions is essential to understanding the 
microbiome’s role in health and disease. However, at present, functional genetic studies of diverse 
natural mammalian gut microbiomes remain challenging, due to a lack of genetic tools for bacteria 
outside of a handful of well-studied model organisms. Altering the metagenome of a complex 
microbial community requires novel platform technologies for genetic engineering which can 
operate in a generalized fashion across many different host organisms. In this thesis, I present two 
novel genetic tools designed for genetic modification of bacterial communities.  
The first, the Cas-Transposon platform, is a host-independent targeted genome editing tool 
that utilizes programmable, targeted transposases to mediate site-specific gene insertions into user-
defined loci. The Himar1 transposase naturally inserts transposases into random TA dinucleotides 
in a genome, but when fused to the dCas9 RNA-guided, DNA-binding protein, the fusion protein 
Himar1-dCas9 targets transposon insertions to a single TA site. The activity of Himar1-dCas9 was 
characterized using in vitro experiments, demonstrating that site-specific transposition is dependent 
on guide RNA (gRNA) orientation relative to the target site and the sequence surrounding the target 
site, but robust to variations in DNA and protein concentration, presence of background DNA, and 
temperature. We additionally showed that the Cas-Transposon platform is capable of performing 
site-specific transposition into a plasmid in vivo in E. coli, although further optimization of the system 
may be necessary to effect site-specific transposition into a genomic locus. The Himar1-dCas9 
protein is the first example of a transposase that inserts transposons into locations programmable 
by an RNA, making it a novel tool for gene insertion and knockout in potentially any organism, 
without relying on DNA repair by a host cell. 
Metagenomic Alteration of Gut microbiome by In situ Conjugation (MAGIC) is an approach 
to directly modify gut bacteria in their native habitat by harnessing naturally occurring horizontal gene 
transfer activity to deliver engineered DNA. Because many gut bacteria are difficult to cultivate and 
thus difficult to genetically manipulate in the laboratory, MAGIC uses donor bacteria, delivered 
directly into the gut environment, to conjugate mobile vectors bearing engineered genetic payloads. 
Using payloads with selectable markers, we identified organisms across 4 major phyla of gut bacteria 
that were amenable to genetic modification with libraries of conjugative vectors we created. Using a 
lab-adapted E. coli strain as a donor, we achieved transient expression of the engineered payload in 
the microbiome. We also demonstrated that engineered native gut bacteria containing conjugative 
vectors could be deployed back into the gut to stably recolonize and mediate secondary transfer of 
the payload into other microbes, potentially enabling long-term infiltration of the payload into the 
metagenome. The results from this study suggest that both short-term and long-term genetic 
alteration of the metagenome are possible by choosing different donors, and that the MAGIC platform 
could enable development of more diverse microbial chasses for synthetic biology applications. 
MAGIC could also be used to create personalized engineered probiotics for diagnostic or therapeutic 
applications. In Chapter 4 of this thesis, we explored the targeted use of MAGIC to genetically modify 
Segmented Filamentous Bacteria, a gut commensal that is important for immune regulation but 
recalcitrant to in vitro cultivation. 
The Cas-Transposon and MAGIC technologies expand our capabilities in the areas of 
targeted genome editing and gene delivery into bacteria, respectively. Together, they form a suite of 
complementary approaches to genetically engineer undomesticated gut commensal bacteria and 
probe the functional genetic networks in the gut microbiome, which will enhance our understanding 
of microbiome ecology and host-microbiome interactions. In addition, the expanded range of genetic 
manipulations made possible by these tools may enable production of more diverse, perhaps 
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Chapter 1: Introduction 
 
Functional studies of host-microbiome interactions require novel genetic engineering 
tools for microbial communities 
Over the past two decades, human-associated microbiomes have increasingly been 
appreciated as essential components of the human body that play important roles in maintaining 
homeostasis. As a result of foundational advances in -omics technologies, it has become easier 
to catalog the diverse microbes that make up our microbiomes and to explore their genomes, 
transcriptomes, and proteomes1-4. Dysbiosis, a microbiome imbalance or impairment, has been 
associated with a wide range of disease states, including Clostridium difficile infection, 
inflammatory bowel disease, colorectal cancer, and metabolic syndrome5, 6. While it has become 
relatively straightforward to characterize microbiomes by sequencing approaches, the more 
challenging problem that remains is understanding the mechanisms by which specific genes and 
proteins function to shape microbiome ecology, influence host physiology, and cause disease. To 
gain a mechanistic understanding of microbial ecology and host-microbiome interactions and to 
engineer native commensal microbiota in useful ways, novel genetic tools for manipulating 
microbial communities are needed. 
In humans, the gut microbiome forms the bulk of commensal microbes and modulates 
host physiology in a variety of ways. The gut microbiome contains up to 100 trillion cells 
comprising about 1000 species of bacteria, which collectively contain millions of genes, two orders 
of magnitude more than the genes encoded by the human genome7, 8. The vast majority (90-99%) 
of genes in the metagenome (the total genomic content of the microbiome) are bacterial, with the 
remainder being of archaeal, eukaryotic, or viral origin8, 9. Four bacterial phyla dominate the 
microbiome: Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria10. The composition of 
the gut microbiome varies greatly between individuals and is influenced by age, diet, lifestyle, 
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environment, and disease, but the microbiomes of individual adults remain relatively stable over 
time9, 11, 12. Despite this divergence in microbiome compositions, studies have shown that broad 
functional categories of genes are shared between the metagenomes of individuals4, 11, 13. To give 
one example, a study of 18 subjects found no species-level phylotypes shared between all 
subjects, but 93% of functional gene categories were shared among all subjects13. This 
conservation of functional gene categories suggests that the gut microbiome performs similar 
functions across individuals with divergent microbiome compositions, although differences 
between microbiomes at finer scales (i.e., specific genes) contribute to functional differences 
between individuals11. 
The diverse functions encoded in the genomes of gut microbes enable microbes to 
perform essential roles in host physiology, including metabolism, immune system regulation, 
pathogen defense, and neural signaling. Gut microbes break down fibers in food, producing short 
chain fatty acids that nourish colonocytes and activate G-protein-coupled receptors to modulate 
hormonal signaling14. Gut microbes are also necessary for hydrolyzing and biotransforming bile 
salts in the intestine15. The gut microbiome alone is sufficient to drive major changes in host 
metabolism; for example, gut microbiota transplants from obese human subjects or patients with 
kwashiorkor (a form of protein malnutrition) into germ-free mice recapitulated these phenotypes 
in the mice16, 17. Gut microbes can affect drug metabolism, an important consideration in 
medication management. Eggerthella lenta is known to inactivate digoxin18, while the 
chemotherapeutic drug CPT-11 is activated by gut bacteria, producing severe diarrhea as a side 
effect19. Commensal gut bacteria modulate the development of the mammalian immune system 
and provide resistance to pathogen invasion20, 21. The gut microbiome also affects neural signaling 
within the enteric and central nervous systems, working through the gut-brain axis to modulate 
depression-, anxiety-, and stress-related behavior22, 23. 
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The insight that the gut microbiome is involved in host physiology raises the questions of 
which microbes are responsible for particular host-microbiome interactions, and by what 
functional mechanisms these microbes affect the host and/or each other. Metagenomic or 
metatranscriptomic sequencing studies of the microbiome during a given physiological state 
reveal associations of that state with specific microbes that are increased in abundance or 
microbial genes that are upregulated, but associations do not imply causation. Changes in the 
microbiome could be an effect of the host physiological state, rather than the cause. To definitively 
identify a particular microbe or gene as being causal for a host physiological state, it necessary 
to alter the abundance of that microbe or gene product and show that the associated host state 
occurs as a consequence of the change in the microbiome.  
At present, several methods are used alter gut microbiomes to interrogate their function, 
but all are subject to limitations of specificity, magnitude of alteration, or biological relevance. 
Chemicals, such as prebiotics or xenobiotics, can be introduced into the gut environment to 
modify the abundance of microbes or microbial products. Prebiotics are chemical substrates that 
selectively induce microbial growth or activity. In the context of the gut microbiome, prebiotics are 
usually oligosaccharides or polysaccharides that promote growth of Bifidobacteria and 
Lactobacilli24. Xenobiotics are compounds foreign to the native environment that are intended to 
modulate microbial function or growth. Xenobiotics include antibiotics, which are commonly used 
to deplete the microbiome, as well as chemicals with more targeted functions. For example, β-
glucuronidase inhibitors have been used to reduce toxicity of the drug CPT-11 in mice by 
inactivating the bacterial β-glucuronidase enzymes that reactivate the drug19. A structural analog 
of choline inhibits trimethylamine (TMA) production by gut microbes, which prevented 
development of atherosclerosis in mice caused by a downstream metabolite of TMA25. While 
chemical modifiers of the microbiome are useful for manipulating microbial function, they may act 
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nonspecifically, affecting wide swathes of bacteria, which makes their effect on the microbiome 
difficult to predict. 
Another approach to modifying the gut microbiome is introduction of novel bacteria into 
the ecosystem. Probiotics are live bacteria which confer a benefit to the host when administered 
in adequate amounts26. Well-studied probiotics include Lactobacillus rhamnosus, which 
decreases stress-induced anxiety- and depression-related behaviors in mice by modulating 
signals through the vagus nerve27, Bifidobacterium species, which break down plant 
carbohydrates to produce short-chain fatty acids28, and E. coli Nissle 1917, which defends against 
colonization by enteric pathogens29-31. Engineered probiotics have also been developed to deliver 
synthetic gene products in vivo; in particular, Lactococcus lactis has been used as a probiotic 
chassis for expressing anti-tumor necrosis factor (TNF)-α antibodies, IL-10, and TGF-β1 in the 
gut32-34. However, probiotics are not native to natural gut microbiomes in animals, and they face 
resistance to long-term colonization of the gut by the indigenous microbiota35-37. Any observed 
effects on host physiology occur transiently for the duration of probiotic administration35, 37 and do 
not necessarily reflect the function of native microbes within the gut without the perturbation of 
probiotic administration. 
Studies to interrogate host-microbiome interactions have also utilized the engraftment of 
commensal gut bacteria into new hosts, in order to observe the effect of the bacteria. Fecal matter 
transplants (FMT), which contain the entire fecal microbiome, from human donors into germ-free 
were used to demonstrate the microbiome’s role in causing obesity16 and kwashiorkor17. FMT has 
also been successfully used in humans and mice to treat Clostridium difficile infection (CDI)38, 39.  
Engraftments of specific strains of bacteria have also been used to study the function of those 
strains in greater detail. For example, Clostridium scindens, a secondary bile acid-synthesizing 
bacterium, is associated with resistance to CDI in both mice and humans. When mice that were 
normally susceptible to CDI were colonized with C. scindens, the mice had a reduced rate of CDI, 
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likely due to production of secondary bile acids by C. scindens that were toxic to C. difficile40. 
Genetically engineered mutants of the gut symbiont Clostridium sporogenes were engrafted into 
mice to demonstrate that a metabolic pathway in this bacterium produces aromatic amino acid 
metabolites, which accumulate in the host serum and alter host immune activation and intestinal 
permeability41. Like probiotic studies, however, commensal bacteria engraftment studies are also 
potentially limited by colonization resistance42. Engraftments are typically performed on germ-free 
animals, on animals colonized with a few defined bacterial strains, or with co-administration of 
antibiotics to suppress the native microbiota, which facilitates the colonization of an exogenous 
strain but limits the biological applicability of these studies to animals with robust natural 
microbiomes. 
Bacteriophages represent another route for modifying microbiomes. Phages can be used 
to infect and lyse their specific host cells to selectively deplete those hosts from the population; 
oral administration of phages has been used to selectively eliminate enteric pathogens such as 
Shigella and Listeria from mice without significantly affecting the rest of the microbiome43, 44. 
Engineered phages can also be used to genetically modify their hosts through lysogeny, 
delivering new genetic functions into the hosts45. However, because phages only infect specific 
hosts, targeting any given bacterial strain in the gut microbiome requires identification and 
cultivation of associated phages. At the present time, using phages to infect any given strain in 
the microbiome remains challenging, though the gut phage-ome is becoming better characterized 
and may yield useful phages for manipulating a wide variety of bacteria in the future46. 
Resistance to colonization makes engraftment of foreign bacteria into a diverse 
microbiome challenging, while approaches to increase or deplete bacteria or gene products using 
chemicals are non-specific. Direct genetic manipulation of gut microbes in their native 
environment would enable better targeted functional studies of gut microbiome ecology and host-
microbiome interactions. Engrafting a novel genetic function or knocking out a genetic function 
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from the metagenome, without relying on introducing exogenous bacteria into the microbiome, 
would more directly show the effect of those functions. At present, however, genetic engineering 
of natural microbial communities remains an open challenge. Gut bacteria are obligate or 
facultative anaerobes, and many are difficult to cultivate in vitro, limiting their genetic tractability. 
Most genetic tools and protocols for manipulating bacteria are highly optimized for a small handful 
of well-studied model organisms, and are not easily generalizable to the diverse array of 
mammalian gut commensals. 
This thesis aims to address the challenge of engineering gut microbes within their native 
context by introducing two novel platform technologies for genetically engineering bacteria. The 
first is the Cas-Transposon system for host-independent, programmable, targeted genomic 
integrations, described in Chapter 2. The second is a platform technology for genetically 
engineering gut microbes in their native environment, Metagenomic Alteration of Gut microbiome 
by In situ Conjugation (MAGIC), described in Chapter 3. In Chapter 4, I present an application of 
the MAGIC technology to genetically modify Segmented Filamentous Bacteria in situ, as SFB is 
a gut commensal that remains very difficult to cultivate in vitro. These technologies provide 
solutions for the challenges of targeted genome editing in prokaryotes and delivering engineered 
synthetic DNA into a diverse community of microbes. By bypassing the reliance on host DNA 
repair machinery and in vitro cultivation of microbes, which limit the efficacy of many currently 
available genetic engineering tools, Cas-Transposons and MAGIC are complementary tools that 
can be broadly applied to prokaryotes. These tools have the potential to greatly expand the range 
of possible genetic manipulations in the gut microbiome and the set of genetically tractable 
microbial chasses for synthetic biology applications. 
 
Current approaches to targeted genome editing in bacteria 
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Experimentally probing the functions of gene networks and rationally engineering useful 
new functions in a microbiome requires platform technologies for genome editing that can be 
applied to many diverse species. Over the years, a number of methods have been developed for 
targeted modification of bacterial genomes47. Today, commonly used methods to edit bacterial 
genomes take one of two approaches: using host DNA replication and/or repair machinery to 
incorporate exogenous dsDNA or ssDNA, or relying on one of several host-independent enzymes 
to modify the genome. 
Host-dependent methods for targeted genome editing include nuclease-guided genome 
editing, recombineering, and Multiplex Automated Genome Engineering (MAGE). Targeted 
nucleases are used in conjunction with host DNA repair systems to incorporate specific genomic 
edits. The nuclease creates a double-stranded break at the target site, which is repaired by 
homologous recombination (HR) to incorporate a synthetic template DNA containing the desired 
edit. Targeted nucleases include zinc-finger nucleases (ZFNs)48 and transcription activator-like 
effector nucleases (TALENs)49, which consist of a non-specific FokI nuclease domain fused to a 
DNA-binding domain that recognizes a specific motif. A more versatile and programmable class 
of nucleases are Cas nucleases associated with Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR) systems, which originally evolved as an immune system for 
bacteria and archaea50-52. Cas nucleases cleave invading foreign DNA with the help of 
complementary RNAs encoded by CRISPR arrays53. A modified CRISPR system from 
Streptococcus pyogenes is commonly used for gene editing, in which a synthetic guide RNA 
(gRNA) targets Cas9 nuclease to an NGG protospacer adjacent motif (PAM) sequence54.  Since 
the specificity of DNA cleavage is easily programmed by small RNA guide sequences, the 
CRISPR-Cas system has been used for genome editing in many eukaryotic systems including 
yeast55, fruit flies56, zebrafish57, mice58, and humans59, 60, where the DSB can be repaired by HR 
or by non-homologous end joining (NHEJ) to create indels. In bacteria, which generally do not 
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have NHEJ systems61, CRISPR-Cas genome editing utilizes  HR62. CRISPR-Cas can also be 
used as antimicrobial system by cutting specific DNA sequences63, 64. While the nuclease/HR 
approach to genome editing has become ubiquitous, efficiency of HR remains a limiting factor in 
genetically modifying bacteria. 
Recombineering uses host-specific phage proteins to recombine DNA with homologous 
flanking ends into the genome, increasing the efficiency of HR over native bacterial DNA repair. 
In E. coli, lambda red recombineering uses lambda phage proteins Exo, Beta, and Gam to 
enhance recombination efficiency, but the efficiency remains relatively low, particularly with larger 
DNA insert sizes of several kb65. Bacteria are able to incorporate short, synthetic ssDNA 
oligonucleotides during DNA replication with higher efficiency. MAGE utilizes this insight, 
delivering short (30 to 100 bp) ssDNAs that containing desired modifications into the cell during 
cell division66. The oligonucleotides anneal to the lagging strand of DNA replication forks and 
function as synthetic Okazaki fragments that get incorporated into daughter cells. Multiple 
genome edits can be incorporated simultaneously. Similarly to recombineering, the efficiency of 
oligo incorporation is enhanced by the lambda-red proteins. While recombineering and MAGE 
have been adapted to function in organisms other than E. coli, this process requires searching for 
phage proteins specific to each organism with the same functions as the lambda phage proteins67 
and laborious optimization for each organism, limiting the utility of these methods for genome 
editing across diverse species. 
Host-independent approaches to genome editing may be expected to function more 
robustly across different host backgrounds and include recombinases, group II introns, and base 
editors. Recombinases such as Flp68 and Cre69 mediate recombination at defined recognition 
sequences to efficiently integrate large pieces of heterologous DNA, but have limited 
programmability since their DNA-recognition domains are challenging to retarget to other DNA 
motifs70, 71. Group II introns are retrotransposons that use an RNA intermediate to complement an 
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insertion site; the RNA is reverse-transcribed by the intron-encoded protein for incorporation into 
the DNA72. Group II introns function host-independently and have been used to make genomic 
insertions in a variety of Gram-negative and Gram-positive organisms73, 74. However, not all genes 
may contain suitable target sites for insertion, and insertions are limited in size to below 2kb47, 74. 
Recently, base editors, proteins consisting of a nucleotide deaminase fused to an RNA-guided, 
catalytically dead dCas9 protein, have been developed to make single-base substitutions at 
gRNA-targeted loci75, 76. This approach may be powerful going forward as a host-independent 
method for making controlled SNPs in bacteria and eukaryotes. 
Presently, there is a lack of programmable host-independent methods for making targeted 
large insertions into bacterial genomes. To address this problem, we developed the Cas-
Transposon platform, which uses dCas9/gRNA-guided Himar1 transposases to catalyze targeted 
transposition into the genome. Himar1 is a member of the mariner family of transposases 
originating from the horn fly Haematobia irritans77 and naturally inserts multi-kb transposons 
randomly into TA dinucleotides, making it a useful tool for bacterial mutagenesis78. By fusing 
Himar1 to an RNA-guided DNA-binding protein, the transposase activity is limited to the locus at 
which it is tethered. In Chapter 2, we demonstrate that the Himar1-dCas9 fusion protein mediates 
site-specific transposon insertions robustly in vitro and show preliminary evidence of in vivo 
function in an E. coli plasmid assay. While further optimization is necessary to improve the Cas-
Transposon system’s function in vivo, this work represents the first demonstration of a novel mode 
of targeted genome editing applicable to any organism. 
 
Gene delivery into diverse natural microbiomes 
The first step in genetically engineering a microbe is introducing DNA into the cell. 
Traditional techniques for bacterial transformation include electroporation, chemical 
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transformation, and natural competence. While over 80 species of bacteria have been 
documented to be genetically engineerable by these in vitro methods, the necessary conditions 
for transformation in these microbes vary widely and are laborious to optimize for each individual 
species79. These transformation techniques also require microbes that are cultivable in vitro, 
which excludes a significant fraction of fastidious gut bacteria that remain uncultivable at 
present80, 81. 
In nature, microbes frequently acquire and propagate new DNA via horizontal gene 
transfer, the movement of DNA between different organisms. Horizontal gene transfer (HGT) 
occurs by one of three modalities: transformation, or uptake of DNA from the environment; 
conjugation, where DNA is transferred between cells in direct contact by type IV secretion 
systems82; and transduction, in which foreign DNA is introduced to a cell by an infecting virus. 
Past horizontal gene transfer events into an organism can be inferred by analyzing its genome; 
segments of DNA with high sequence similarity to DNA from otherwise distantly related organisms 
are more likely to have originated from HGT rather than vertical evolution83. Metagenomic studies 
have shown that the human gut microbiome has very high rates of HGT compared with other 
naturally occurring microbiomes, such as soil or marine microbiomes84. HGT allows microbes to 
rapidly acquire novel genes that enhance their fitness in the highly competitive gut environment. 
These horizontally transferred genes encode functions such as carbohydrate metabolism85, 86, 
formation of cell surface structures that enhance colonization and cell-cell signaling85, antibiotic 
resistance87, and virulence factors88. The pool of mobile genes can confer very different 
phenotypes to different strains of the same species89, and thus engineering the mobilome is 
potentially a powerful strategy for functionally altering a microbiome. 
Conjugation can result in gene transfer events across very broad ranges of species. The 
vectors of conjugative gene transfer include plasmids, closed circles of DNA that self-replicate in 
a subset of bacteria, and integrative conjugative elements (ICEs), which propagate by stably 
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integrating into the recipient organism’s genome. Conjugative plasmids have an essential 
backbone consisting of genes involved in self-replication and an origin of replication (oriR), as 
well as an origin of transfer (oriT) that binds to conjugative transfer proteins, which nick the 
plasmid and transfer it through a pilus as a single stranded DNA90. Plasmids may be self-
transmissible, if they contain all necessary genes for conjugative transfer, or mobilizable, if they 
contain an oriT that can be mobilized by another conjugative element. ICEs include elements that 
are mobilized by integrases, which mediate recombination into a specific recognition sequence, 
and transposons, which integrate into random loci. Successful transfer of mobile elements 
between species or strains requires expression of replication and maintenance systems in the 
recipient, and avoidance of bacterial defense mechanisms against invading foreign DNA, such as 
CRISPR systems91 and restriction/modification systems92. Experimental studies of the host 
ranges of these genetic elements, particularly plasmids, have historically focused on analyses of 
conjugation between two strains or species93, 94. Recently, advances in next-generation 
sequencing and high-throughput screening have enabled experimental tracking of plasmid 
transfer into diverse natural microbiomes, such as the soil microbiome95. The high frequency of 
conjugative HGT between distantly related bacteria observed makes conjugation a promising 
method of gene delivery into diverse microbiomes.  
MAGIC harnesses HGT in the gut to deliver engineered gene circuits into native gut 
bacteria by in situ conjugation. We designed a set of broad host-range conjugative plasmid 
vectors containing a genetic payload consisting of an antibiotic resistance gene and a GFP gene 
and disseminated them into the gut microbiota of conventionally raised mice, using an engineered 
E. coli strain as a plasmid donor. From fecal samples, we were able to isolate and identify in situ 
transconjugants from across 4 major phyla of gut bacteria using in vitro antibiotic selection and 
FACS enrichment of transconjugants. Though these transconjugants were only transiently 
present in feces, genetically modified native gut microbiota containing MAGIC vectors were 
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capable of long-term colonization of the gut when orally gavaged to mice and also mediated 
secondary HGT of the vectors into new recipients. By changing the donor strain (laboratory 
adapted E. coli vs. an individual host-adapted commensal strain) and vector parameters (origins 
of replication, regulatory elements), the MAGIC platform can be adjusted to actuate different 
scales of metagenome modification, in terms of time duration and range of transconjugants. This 
work is described in Chapter 3. 
MAGIC potentially enables genetic engineering in organisms that we are unable to 
cultivate in vitro. Segmented Filamentous Bacteria (SFB) is difficult to cultivate, but is a key player 
in regulating intestinal mucosal immunity21, 96 and has not yet been genetically manipulated. In 
Chapter 4, we explore the possibility of applying MAGIC to genetically modify SFB without in vitro 
cultivation. Here, we explain the design principles involved in designing genetic vectors for an 
organism with no prior genetic tools and show data from preliminary experiments. 
 
Impact of novel genetic engineering tools 
 The overarching motivation for development of the Cas-Transposon and MAGIC 
technologies is to enable a wider range of genetic manipulations in more diverse bacteria, in order 
to genetically manipulate naturally occurring microbiomes. The ability to perform make specific 
modifications to the metagenome would be powerful for functional genetic screens of the 
microbiome as a unit. Additionally, the tools described here would facilitate engineering of native 
gut microbes as probiotics that perform useful functions, such as sensing inflammation97, 98 or 
small molecules99 and delivering therapeutic molecules100 into the gut. To date, only a small 
handful of bacterial strains (E. coli, Salmonella typhimurium, several Lactobacillus strains, and 
several Bacteroides strains) have been genetically engineered as chasses for these purposes, 
but MAGIC could enable delivery of synthetic gene circuits into a wider range of microbes, 
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possibly personalized for individuals in order to actuate a longer-term effect. These improvements 
would advance our functional understanding of the gut microbiome as it relates to health and 
physiology and provide novel solutions for diagnosing and treating diseases of the microbiome. 
The technologies described here would also be broadly applicable to studying and manipulating 
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Efficient targeted insertion of DNA into a genome is a major challenge in genome editing. 
While CRISPR-Cas9 genome editing has become widely used in diverse organisms, reliance on 
the host organism’s DNA repair machinery to incorporate DNA limits the efficiency of insertion in 
a size-dependent manner. Recombinases, which are commonly used to insert operon-sized 
constructs into genomes, are restricted to existing recognition sites in the genome and are difficult 
to target to other loci. Here, we describe the Cas-Transposon platform for genome editing, in 
which hyperactive Himar transposases fused to RNA-guided dCas9 proteins mediate 
programmable, site-specific transposon insertions. Himar transposases naturally cut and paste 
multi-kb DNA transposons into new, random TA dinucleotides; when the Himar transposase is 
fused to dCas9, which binds DNA complementary to a guide RNA (gRNA), the transposase 
becomes tethered to a target site specified by the gRNA and increases the rate of transposition 
into a nearby TA insertion site. Using in vitro assays, we demonstrated that Himar-dCas9 fusion 
proteins enriched transposon insertions at a single targeted TA site over 300-fold compared to a 
random transposase, and that site-specific transposition is dependent on target choice but robust 
to log-fold variations in protein, donor DNA, target DNA, and background DNA concentrations. 
We validated that Himar-dCas9 was also capable of mediating site-specific transposition into a 
target plasmid in E. coli, but did not find evidence of site-specific transposition into a targeted 
genomic locus in mammalian cells. While further optimization of the Cas-Transposon system is 
necessary to improve performance for genome editing, we have engineered the first synthetic 
transposase capable of host-independent, programmable targeted insertions, which represents a 






Genome engineering relies on molecular tools that enable targeted and specific 
modification of a genome to introduce insertions, deletions, and substitutions. While numerous 
advances have emerged over the last decade to produce programmable editing and deletion of 
bacterial and eukaryotic genomes47, targeted genomic insertion has been a long outstanding 
challenge. Integration of desired heterologous DNA into the genome needs to be precise, 
programmable, and efficient; three key parameters of any genome integration methodology. 
Currently available genome integration tools are limited by one or more of these factors. 
Recombinases such as Flp68 and Cre69 that mediate recombination at defined recognition 
sequences to integrate heterologous DNA have limited programmability, since their DNA-
recognition domains are challenging to retarget to other DNA motifs70, 71. Site-specific nucleases, 
such as Cas953, 59, zinc finger nucleases (ZFNs)48, and transcription activator-like effector 
nucleases (TALENs)49, can be programmed to generate double-strand DNA breaks that are then 
repaired to incorporate a template DNA, but this process relies on host homology-directed repair 
machinery, which are variable and often inefficient, especially as the size of the DNA insertion 
increases.  
Transposable elements are widespread natural selfish genetic systems capable of 
integrating large pieces of DNA into both prokaryotic and eukaryotic genomes. Amongst various 
transposable elements described101, 102, the Himar1 transposon from the horn fly Haematobia 
irritans77 has been coopted as a popular tool for insertional mutagenesis. The Himar1 transposon 
is mobilized by the Himar1 transposase, which like other Tc1/mariner-family transposases, 
functions as a homodimer to bind the transposon DNA at the flanking inverted repeat sequences, 
excise the transposon, and paste it into a random TA dinucleotide on a target DNA77, 103-105. Himar1 
transposition requires no host factors for transposition and functions in vitro77, in bacteria78, and 
in mammalian cells106, and is capable of inserting transposons over 7kb in size107. A hyperactive 
mutant of the transposase, Himar1C9, which contains two amino acid substitutions and increases 
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transposition efficiency by 50-fold108, has enabled the generation of genome-wide transposon 
insertion mutant libraries for genetic screens in diverse microbes109-111. However, since Himar1 
transposons are inserted randomly into TA sites, their utility in targeted genome insertion 
applications has thus far been limited. 
One approach to potentially increase the specificity of otherwise random transposon 
insertions is to increase affinity of the transposase to specific DNA motifs. Indeed previous studies 
have described fusing transposases to a DNA-binding protein (DBP) domain to increase targeting 
of transposon insertions to specific genetic loci. Fusing the Gal4 DNA-binding protein to Mos1 (a 
Tc1/mariner family member) and piggyBac transposases altered the distribution of integration 
sites112 to near Gal4 recognition sites in plasmid-based assays in mosquito embryos. Fusion of 
DNA-binding zinc-finger or transcription activator-like effector proteins to piggyBac enabled 
integration into specified endogenous genomic loci in human cells113-115. ISY100 transposase 
(also a Tc1/mariner family member) has also been fused to a Zif268 Zinc-finger domain to 
increase specificity of transposon insertions to DNA adjacent to Zif268 binding sites116. While 
these studies demonstrated the feasibility of the transposase-DBP fusion approach for targeted 
genome insertion, the DBP used thus far are still challenging to reprogram and to limit off-targeting 
effects.   
More recently, protein fusions using a catalytically inactive Cas9 nuclease (dCas9) as an 
RNA-guided, DNA-binding protein have enabled manipulation of genomic DNA and gene 
expression near user-defined loci. dCas9 targeted to a particular gene by a synthetic guide RNA 
(gRNA) blocks transcription by steric hindrance of RNA polymerase117, while dCas9-transcription 
activator fusions targeted to a promoter enhance gene expression118. The FokI-dCas9 fusion 
nuclease is a directed nuclease that functions as a dimer, and thus provides increased site-
specificity over the Cas9 nuclease119, 120. Base editors, fusion proteins consisting of a deaminase 
and dCas9, enable single-base substitutions at gRNA-targeted loci75, 76. dCas9 has also been 
tethered to the Gin serine recombinase to facilitate increased recombination specificity at a 
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targeted recombinase recognition site in the human genome121. At this time however, no dCas9-
transposase fusions have been demonstrated for dCas9-targeted transposition into a genomic 
locus; a recent study by Luo et al. showed that a dCas9-piggyBac transposase protein did not 
have targeted activity115. 
In this study, we developed a novel platform technology, Cas-transposons, that unites the 
DNA integration capability of the Himar1 transposase and the programmable genome targeting 
capability of dCas9 to enable site-specific transposon insertions at user-defined loci in an easily 
generalizable fashion. The system uses Himar1-dCas9 fusion proteins, tethered by a gRNA to a 
specific locus, to integrate transposons carrying synthetic genetic payloads into that locus (Figure 
2.1a). We demonstrated targeted transposon integration by Himar1-dCas9 proteins in both cell-
free in vitro reactions and in E. coli. The Cas-transposon technology can potentially be optimized 
to function in any prokaryotic or eukaryotic cells, because the Himar1-dCas9 protein requires no 
host factors to function. Cas-transposons may be a useful tool for various applications such as 
metabolic pathway engineering122 (e.g., simultaneous integration of operon-size pieces of DNA 
and knockout of an endogenous gene) or emergent gene drive technologies123 (e.g., targeted 
propagation of engineered traits across populations). 
 
2.3 RESULTS 
Design of a targeted transposase protein 
 We designed proteins to mediate programmable, site-specific transposition using key 
insights from previous studies on Himar1 transposases and dCas9 fusion proteins. The dCas9 
protein from Streptococcus pyogenes, which is the Cas9 nuclease with 2 amino acid substitutions 
in cleavage catalysis sites, has been well-characterized and used as the RNA-guided, DNA-
binding domain in a number of fusion proteins, including DNA base editors and transcriptional 
activators. The Himar1C9 hyperactive transposase efficiently catalyzes transposition in diverse 
species and in vitro, indicating that it acts host-independently and robustly in a variety of 
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environments and may be amenable to protein modifications. For the purposes of exploring 
transposon insertion sites by next-generation sequencing, the Himar1 transposon features the 
advantage of a MmeI restriction site in its inverted repeat sequences, which enables isolation of 
transposon-insertion site junctions by restriction digest. Because the Himar1 transposase only 
inserts transposons into TA sites, a targeted Himar1-dCas9 fusion protein could potentially enable 
single-nucleotide precision in insertions, whereas transposases with less well-defined insertion 
sites (such as Tn5124) may not achieve that level of precision targeting.  
Because protein fusions to the N-terminus of dCas9 and the C-terminus of mariner-family 
transposases have been previously described, we fused the C-terminus of Himar1C9 to the N-
terminus of dCas9 using flexible protein linkers XTEN (N-SGSETPGTSESATPES-C) and L2 (N-
GHGTGSTGSGSS-C), which were the two most optimal linkers used to construct FokI-dCas9 
fusion proteins119. We performed preliminary tests to verify that both domains of the Himar1C9-
dCas9 fusions were functional. To check that dCas9 was capable of binding a DNA target 
specified by a gRNA, we expressed the Himar1C9-L2-dCas9 fusion in an E. coli strain with a 
genomically integrated mCherry gene, along with 2 gRNAs targeting mCherry (gRNAs 5 and 16 
in Table 2.1). If the Himar1C9-dCas9 fusion bound the mCherry genomic target, then the protein 
would sterically hinder RNA polymerase and decrease transcription of the gene, thereby 
decreasing mCherry fluorescence. Indeed, we observed mCherry knockdown by Himar1C9-
dCas9, indicating that the DNA binding functionality was intact in the fusion protein (Suppl. Figure 
S2.1a). We verified that the transposase activity was also intact in Himar1C9-L2-dCas9 using an 
E. coli conjugation assay (Suppl. Figure S2.1b). 
  
Design of an in vitro reporter system for targeted transposition events by Himar1C9-dCas9 
We first explored the targeted transposition activity of a purified Himar1C9-dCas9 fusion 
protein within in vitro reactions. The fusion protein Himar1-XTEN-dCas9 (HdCas9) was cloned 
into a C-terminal 6xHis-tagged expression vector and purified from E. coli by nickel affinity 
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chromatography. Purified HdCas9 was mixed in a reaction buffer with a transposon donor plasmid 
pHimar6, which contained a Himar1 transposon bearing a chloramphenicol resistance marker; a 
transposon target plasmid pGT-B1, which contained the GFP gene; and one or more gRNAs 
targeted to various loci along GFP (Figure 2.1b, Tables 2.1-2.2).  
We analyzed transposon insertions into the target plasmid by several assays. qPCR of 
target plasmid/transposon junctions, using one primer complementing the transposon DNA and 
one primer complementing the target plasmid, enabled quantification of transposons that were 
inserted into the target plasmid, as well as qualitative assessment of transposition specificity 
based on the enrichment of PCR products of the expected size (Figure 2.1b-c). For every 
transposon/target junction PCR, we also performed a control PCR amplifying the target plasmid’s 
backbone to normalize for DNA input between samples. Relative Cq measurements shown in this 
study are the differences between these two Cq values. PCR primers used in this study are listed 
in Table 2.3. Next-generation transposon sequencing enabled quantitative measurement of the 
distribution of inserted transposons within the target plasmid (Suppl. Figure S2.2). Finally, 
transposition reaction products could be transformed into competent E. coli. Because the donor 
plasmid’s R6K origin of replication inhibits replication in E. coli without the pir replication gene, we 
could select for transformants of the target plasmid and of target plasmids with an integrated 
transposon. Transposition efficiency was calculated by dividing the number of chloramphenicol-
resistant transformants (recipients of target plasmid with a transposon) by the number of 
carbenicillin-resistant transformants (recipients of target plasmid). Transposition specificity 
among transformants was determined by Sanger sequencing of plasmids from chloramphenicol-
resistant transformants. 
 
Site-specificity of Himar1 transposon insertions is dependent on gRNA orientation.  
Within the in vitro system, we assessed several gRNAs to determine how the spatial 
orientation of the gRNA relative to the target TA site affects site-specificity of transposition. We 
21 
 
designed gRNAs with spacings between 5 and 18 bp from a TA site, targeting either the template 
strand or non-template strand of the GFP gene (Figure 2.2a, Table 2.1). We tested each 
individual gRNA in triplicate reactions using 30 nM purified HdCas9 protein, 30 nM gRNA, 2.27 
nM pHimar6, and 2.27 nM pGT-B1.  
Based on the PCR assay, a single gRNA is sufficient to mediate site-specific transposition, 
but site-specific transposition is dependent on gRNA spacing to the TA target site (Figure 2.2b). 
All gRNA-targeted insertion events occurred at the nearest TA dinucleotide distal to the 5’ end of 
the gRNA, independent of the targeted DNA strand (Figure 2.2a).We observed strong site-
specificity for gRNAs with 7-9 bp spacings and with 16-18 bp spacings, based on the robust PCR 
band for transposon junctions of the expected size (red arrows). At very short spacings (5-6 bp), 
there was no PCR band at the expected junction size, suggesting that the HdCas9 protein 
sterically hinders transposition at locations less than 7bp from the TA target site. At spacings 
between 11-15 bp, there is a faint PCR band at the expected junction size, indicating that 
transposition at those sites may occur, but the site-specific transposition is not optimal. These 
findings are consistent with the previously observed spacing dependence for FokI-dCas9 proteins 
built using the same XTEN peptide linker119. The bimodal distribution of robustly targeting gRNA 
spacings may be due to the DNA double helix providing steric hindrance at intermediate spacings, 
since the spacing peaks are approximate 1 helix turn (~10 bp) apart. Comparison of relative Cq 
values between gRNA-targeted transposases and HdCas9 transposase in the absence of a gRNA 
suggests that transposition may occur at a higher rate in the presence of a targeting gRNA (Figure 
2.2b). This may be due to circumvention of the need for a transposase dimer loaded with a 
transposon to search through space for a TA insertion site, as the gRNA-targeted transposases 
were already bound near an insertion site. We also tested a purified Tn5-dCas9 transposase with 
hyperactive E54K and L372P mutations in in vitro reactions using the same set of gRNAs, but did 
not find evidence of site-specific transposition in any of the reactions based on the PCR assay 
(Suppl. Figure S2.3). 
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To infer the complete distribution of transposon insertions around the target plasmid, we 
performed transposon sequencing on transposition products resulting from 3 GFP-targeted 
gRNAs (gRNAs 4, 8 and 12), a non-targeting gRNA (gRNA 5), and no gRNA (Figure 2.2c). The 
baseline distribution of random transposon insertion events was generated from quadruplicate in 
vitro reactions with no gRNA. In this distribution, transposon insertions were present throughout 
the 6.2 kb pGT-B1 plasmid, with a spike in abundance at position 5999, which is a TA site in the 
middle of a 12 bp stretch of T and A nucleotides. This observation is consistent with the 
observation that Himar1 transposase preferentially inserts transposons into flexible, T/A-rich 
DNA125. gRNA-targeted insertions, on the other hand, were less likely to be inserted into position 
5999 and were enriched at their respective gRNA-adjacent TA site, compared with baseline, to 
varying degrees (Figure 2.2b-c). In particular, gRNA 4, which had an optimal spacing of 8 bp 
from the target TA site, had 42% of all transposon insertions being exactly at the target site, a 
342-fold enrichment over baseline. Comparison of fold-enrichment across different gRNAs 
suggests that the specific target site and flanking DNA also plays a role in the specificity of 
transposon insertions. gRNA 12 had a higher fold-enrichment of insertions at its target site than 
gRNA 8, but a lower fraction of insertions, suggesting that the lack of specificity of gRNA12 may 
be attributable to its target site being disfavored for transposition.  
Given that mariner transposases dimerize in solution in the absence of DNA126, we 
hypothesized that HdCas9 dimerizes spontaneously, and then the active Himar dimer is guided 
to a gRNA-specific target locus by one of the dCas9 domains in the HdCas9 dimer (Figure 2.1a). 
This mechanism of activity is consistent with the observation that a single gRNA is sufficient to 
direct targeted transposition. Further support for this hypothesis comes from in vitro reactions 
containing pairs of gRNAs targeting the same TA site, but complementing opposite strands 
(Suppl. Figure S2.4). If Himar subunits did not spontaneously dimerize, then dimerization of 
HdCas9 would be enhanced by loading two HdCas9 monomers onto the same target plasmid, so 
that pairs of Himar monomers would be tethered in close proximity. We set up reactions in which 
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target DNA was preloaded with paired gRNA/HdCas9 complexes, vs. preloaded with single 
gRNA/HdCas9 complexes, and then mixed with transposon donor DNA (Suppl. Figure S2.4a).  
In all reactions, the final reaction contained 5 nM HdCas9 protein, 5 nM donor DNA, 5 nM target 
DNA, and 2.5 nM of each of two gRNAs. Under these conditions, there was no difference in 
transposition rate or specificity between the gRNA/HdCas9 complexes preloaded as pairs or as 
singletons (Suppl. Figure S2.4b, c). The observation that preloading of pairs of HdCas9 
complexes does not improve transposition is consistent with the hypothesis that transposase 
dimers formed before one of the gRNA/dCas9 domains targeted the dimer to its final location.  
 
Site-specific transposition activity of HdCas9 is robust to variations in protein and DNA 
concentrations.  
To assess robustness of HdCas9 to various experimental conditions and determine the 
optimal parameters for site-specific transposition, we varied the concentrations of (1) protein-
gRNA complexes, (2) transposon donor plasmid DNA, (3) target plasmid DNA, and (4) 
background off-target DNA within in vitro transposition reactions containing a single gRNA (gRNA 
4). We also incubated the reactions at different temperatures and extended the reaction time from 
3 hours up to 72 hours. 
gRNA-guided HdCas9 mediated site-specific transposition events at protein 
concentrations between 3 and 100 nM in reactions with 5 nM donor and 5 nM target plasmids 
(Figure 2.3a). These reactions were also purified and transformed into electrocompetent E. coli 
to assess the efficiency and specificity of transposition (Figure 2.3b); the trend of higher 
transposition at higher transposase concentration is consistent with qPCR measurements. At a 
concentration of 30 nM of the gRNA-HdCas9 complex, the specificity of transposon insertion into 
the targeted TA site was 44% (11/25 colonies); at 100 nM of the gRNA-HdCas9 complex, the 
specificity was 47.5% (19/40 colonies). 
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Site-specific transposition was also robust to variations in DNA concentration. We 
observed site-specific transposition activity in HdCas9 reactions with 5 nM target plasmid DNA 
and between 0.05 to 5 nM donor plasmid DNA, which greater rates of transposition occurring at 
higher DNA concentrations (Figure 2.3c). Similarly, site-specific transposition occurred across a 
wide range of variation in target plasmid DNA (0.25 nM to 10 nM) while donor plasmid DNA was 
kept constant at 0.5 nM (Figure 2.3d). While the absolute rate of transposition (measured by Cq 
of the transposon-target junction qPCR) was higher at higher target DNA concentrations, the 
relative Cq held constant across target DNA concentrations, indicating that a similar proportion of 
target plasmids received a transposon in each reaction. 
gRNA-guided HdCas9 was also able to transpose into a targeted site effectively in the 
presence of background DNA. We added up to 10 times more background E. coli genomic DNA 
than target plasmid DNA to a set of reactions containing 10 nM gRNA-HdCas9, 1 nM donor DNA, 
and 1 nM target DNA. Across all background DNA concentrations tested, HdCas9 was able to 
locate the gRNA-targeted site and insert transposons site-specifically within 3 hours at 30C, with 
no loss of specificity or efficiency (Suppl. Figure S2.5a). When this transposition reaction with 
background DNA was performed at 37C and over longer time courses, to mimic conditions in 
living cells growing at 37C, we observed similar results (Suppl. Figure S2.5b-c, Figure 2.3e-f). 
In the presence of 10 times more background DNA than target plasmid DNA, gRNA-HdCas9 at 
concentrations of 10 nM and 100 nM was capable of mediating site-specific transposition. The 
relative Cq and PCR band intensity of transposon-target junctions increased slightly between 3 
and 16 hours, but PCR bands qualitatively remained at the same level of specificity, suggesting 
that gRNA-guide transposases are faster at locating the target site than catalyzing transposition 
and that the increase in site-specific transposon insertions over time is performed by gRNA-dCas9 
bound transposases. After 16 hours, site-specific transposition events appeared to reach a 
plateau; the loss of specific transposon-target junctions at 72 hours on the PCR gels was most 
25 
 
likely due to degradation of the in vitro reaction components over time (Suppl. Figure S2.5b, 
Figure 2.3e). 
 
HdCas9 mediates site-specific transposon insertions into plasmids in vivo 
 Given that HdCas9 robustly produces site-specific transposon insertions in vitro, we tested 
the ability of HdCas9 to mediate site-specific transposition in two in vivo systems in E. coli and in 
mammalian cells. In the first system, we transformed a set of 3 plasmids into S17 E. coli: pTarget, 
which contains a GFP target gene; pHimar6, the transposon donor plasmid; and a tet-inducible 
expression vector for HdCas9 that also contained 0 or 1 gRNA targeting GFP (Figure 2.4a). We 
grew the cells containing these 3 plasmids for 16 hours on selective agar plates with MgCl2 and 
anhydrotetracycline (ATc) to allow for transposition to occur, and then extracted all plasmids from 
these cells. We measured transposition specificity in these plasmid pools by two methods: PCR 
of transposon-target plasmid junctions, and transformation of the pooled plasmids into competent 
cells and analysis of transposon insertions in individual transformants. 
We first performed a series of validations that the HdCas9 system components functioned 
in vivo. The S17 E. coli strain was transformed with pTarget and one of several HdCas9/gRNA 
expression vectors. By measuring HdCas9-mediated knockdown of GFP in these strains, we 
confirmed that gRNAs (gRNA 1, gRNA 4, and non-targeting gRNA 5) targeted HdCas9 to the 
pTarget plasmid as expected and determined the optimal concentration of ATc for inducing 
HdCas9 expression (Figure 2.4b). Consistent with previously reported results117, gRNA 1, which 
targets the non-template strand of the GFP gene, caused knockdown of GFP expression, but 
gRNA 4, which targets the template strand and does not sterically hinder RNA polymerase, did 
not cause GFP knockdown. HdCas9 concentrations reached saturation at ATc induction levels of 
2 ng/mL, as further increasing the concentration of ATc did not result in further knockdown of GFP 
by gRNA 1. At an ATc level of 1 ng/mL, HdCas9 levels were high enough to bind to some, but not 
all, GFP target sites, based on the partial knockdown of GFP by gRNA 1. We also validated that 
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purified HdCas9 protein with gRNA 1 or gRNA 4 mediated targeted transposition into the GFP 
gene of pTarget in vitro (Figure 2.4c).  
In the in vivo transposition assay, S17 E. coli containing pTarget and an HdCas9/gRNA 
expression vector were transformed with transposon donor plasmid pHimar6. After this 
transformation, cells were plated on selective agar plates containing a saturating concentration of 
MgCl2 to enable transposase activity and 1 ng/mL ATC to induce non-saturating expression of 
HdCas9, in order to avoid overproduction inhibition of the Himar1C9 transposase127. After 16 
hours of growth at 37C, we extracted plasmids from the pooled colonies and analyzed the plasmid 
pools for site-specific transposon insertion events. PCR for transposon-target plasmid junctions 
showed that gRNA 1 produced detectable site-specific transposon insertions into pTarget in 3 out 
of 5 independent replicates (Figure 2.4d). gRNA 4, however, did not produce an enrichment of 
PCR products corresponding to its targeted insertion site. 
We also evaluated site-specificity of transposition by transforming the plasmid pools into 
electrocompetent MegaX E. coli and analyzing individual transformants by colony PCR and 
Sanger sequencing, to confirm that HdCas9 with gRNA 1 mediated precisely targeted transposon 
insertions into pTarget (Figure 2.4a). Analyzing 4 independent plasmid pools from gRNA 1-
expressing cells (Figure 2.4d), we found that 3 out of 4 transformations produced colonies with 
mostly or all site-specific transposition products (Figure 2.4e). In transformations of 4 plasmid 
pools from cells without a gRNA, we did not obtain any transformants containing pTarget plasmids 
with an integrated transposon. This result suggests that in vivo transposition rates into the target 
plasmid were low, but precisely targeted by a gRNA complementary to the non-template strand 
of the GFP gene. Further analysis of transposition products from cells containing gRNA 4 or paired 
gRNAs targeting opposite strands at the same locus is required to determine whether 
transposition is dependent on gRNA strand complementarity and whether paired gRNAs function 
synergistically in vivo. 
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 In a second in vivo test system, we tested the ability of gRNA-targeted HdCas9 to mediate 
site-specific transposition into a genomic locus in Chinese hamster ovary (CHO) cells. We 
transfected a line of CHO cells containing a single-copy, constitutively expressed eGFP gene in 
the genome with two plasmids, one containing a Himar transposon and 0, 1, or 2 gRNA 
expression operons, and the other being an expression vector for HdCas9 (Suppl. Figure S2.6a). 
In the mammalian expression vector, HdCas9 was fused to an N-terminal 3x-FLAG tag and SV40 
nuclear localization signal (NLS) and a C-terminal 6x-His tag. Two gRNAs were designed to target 
the eGFP gene at the same TA insertion site, complementing opposite strands; we tested these 
gRNAs individually and as a pair in vivo, along with a non-targeting gRNA and no gRNA. 
Preliminary in vitro experiments demonstrated that the two gRNAs individually mediated site-
specific transposition by the purified 3x-FLAG-NLS-HdCas9-6x-His protein (Suppl. Figure 
S2.6b).  
The Himar transposon contained a promoterless puromycin resistance gene and mCherry 
gene as selectable markers, both of which would be inserted in-frame into the eGFP locus and 
expressed if correctly targeted by HdCas9 (Suppl. Figure S2.6a). Because the transposon genes 
would only be expressed if the transposon were integrated downstream of an endogenous 
genomic promoter, puromycin selection for transposon mutants was stringent against false 
positive clones resulting from random plasmid integration into the genome. We verified that 
transposon insertions into the target locus resulted in successful expression of puromycin 
resistance and mCherry by constructing a positive control cell line with the transposon cloned into 
that locus (Suppl. Figure S2.6c). 
 Following transfection, we performed antibiotic selection with puromycin to select for cells 
with an integrated transposon. From each transfection of approximately 10^6 cells, we obtained 
about 20 colonies representing independent transposition events. Negative controls for 
transposition, which were transfected with only the transposon donor plasmid, did not produce 
viable cells, indicating clean selection against background random plasmid integration events. All 
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colonies from each transfection were pooled for analysis by flow cytometry and PCR for 
transposon-target junctions. Flow cytometry showed that transfections with no gRNA resulted in 
few eGFP-negative cells, while some transfections with at least 1 gRNA (including the non-
targeting gRNA) produced sizable proportions of eGFP-negative cells (Suppl. Figure S2.6c-d). 
However, PCR for the expected eGFP-transposon junction showed no evidence of targeted 
transposition in any of the transfections, suggesting that the eGFP-negative cells had lost 
expression of eGFP by some other mechanism (Suppl. Figure S2.6e). Although we did not 
observe targeted transposition by HdCas9 into a genomic locus in CHO cells, an optimized 
mammalian testbed for HdCas9 may enable screening for site-specific transposition events 
among larger samples of transposon insertions and shed light on the determinants of site-specific 
transposition in mammalian cells. 
 
2.4 DISCUSSION 
 In this study, we demonstrated for the first time that a random transposase can be 
engineered to insert transposons site-specifically when targeted to a user-defined genetic locus 
by dCas9 and a gRNA. The HdCas9 fusion protein, consisting of a hyperactive Himar1 
transposase and the S. pyogenes dCas9, functions both in vitro and in vivo in E. coli to mediate 
site-specific transposition into a targeted locus on a plasmid. We characterized the activity of 
HdCas9 in vitro across variations in protein and DNA concentration, as well as variations in 
reaction conditions such as temperature and duration, demonstrating that the site-specific 
transposition activity is robust to these parameters, but is dependent on the gRNA orientation 
relative to the target TA insertion site and the surrounding target DNA sequence.  
While we demonstrated targeted insertion into a medium copy-number plasmid in E. coli, 
additional experiments are necessary to determine whether HdCas9 is capable of targeting 
transposon insertions into a genomic locus. A bacterial assay for targeted transposition into the 
genome could be performed by targeting the HdCas9 to a counterselectable genomic marker, 
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such as galK, tetA, or sacB, and selecting for the gene knockout phenotype128, 129. In such a 
scheme, differentiation between knockout and knockdown (via HdCas9 transcription blockade) 
phenotypes is essential, and could be facilitated by only transiently expressing the HdCas9/gRNA 
complex in cells to minimize the knockdown phenotype before initiating counterselection. Given 
the inherent leakiness of inducible expression systems, transient expression of the HdCas9/gRNA 
complex may be best accomplished by conjugation or transformation of a non-replicative vector 
(e.g., an R6K origin of replication plasmid) into the bacteria, so that transformants will lose the 
genes encoding the Cas-Transposon components within a defined period of time. Transient 
presence of the transposon donor vector would also be a useful feature in a genomic targeting 
assay, so that the pool of genomically integrated transposons (as opposed to transposons that 
remain intact in the donor vector) could be easily isolated and analyzed by Tn-seq/INSeq.  
The Cas-Transposon system requires further optimization to enable targeted genomic 
transposon insertions in mammalian cells. We introduced the components of the Cas-Transposon 
system, with the HdCas9 protein and Himar transposon adapted for mammal cells, into CHO cells 
by transfection of 2 expression vectors. We obtained newly antibiotic-resistant clones of cells from 
transfections involving both the HdCas9 expression vector and the transposon donor vector, but 
not control transfections of only the transposon donor vector, indicating that the resistant cells 
had undergone transposition events that inserted the transposon into the genome. However, it 
remains unclear how well the HdCas9 protein and gRNAs were expressed, and how well the 
transposase, gRNAs, and transposon donor vectors were localized in the nucleus to enable 
genomic transposition. Antibody staining for the HdCas9 protein and fluorescence in situ 
hybridization (FISH) using probes for gRNAs and transposons would provide information on the 
localization and relative concentration of each Cas-Transposon system component. Modification 
of regulatory elements on the expression vectors and transfections of different quantities of each 
vector would allow for adjustment of component concentrations. Alternative methods of delivering 
these components into cells, such as electroporation of nucleoprotein complexes, may be 
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required to achieve optimal levels inside the nucleus. More sensitive screens for transposon 
insertions, as well as screening a larger pool of transposon insertions, may also provide greater 
insight into the mechanisms of HdCas9 targeting and transposition catalysis in mammalian cells.  
 The performance of the Cas-Transposon system in both bacterial and mammalian cells 
may be improved by engineering the HdCas9 protein for improved specificity and efficiency. DNA 
base editors consisting of a deaminase fused to a dCas9 protein have improved efficiency when 
two monomers of the deaminase, which operates as a homodimer, are fused to dCas975. Because 
Himar1 likewise functions as a homodimer, the dimer-dCas9 fusion approach may be useful for 
targeting active Himar1 dimers to the desired insertion site. Modification of the Himar1 protein by 
directed evolution or by rational mutagenesis may also improve function. Previous studies have 
shown that Himar1, like other mariner transposases, is rate-limited by the synapsis of transposon 
ends to the protein dimer 127, 130. Himar1 mutants with single amino-acid substitutions in the 
conserved WVPHEL motif have higher rates of transposition than the Himar1C9 mutant, because 
the allosteric inhibition of transposon synapsis is disrupted127. Thus, we speculate that a 
hyperactive WVPHEL mutation, which removes the natural rate-limiting step of transposon 
synapsis, combined with a mutation in the dimerization interface to slow down dimerization of 
Himar1 (normally a fast step), may result in a Himar1 protein that dimerizes more specifically at 
dCas9-targeted locations and then efficiently catalyzes transposition at those sites. In discussing 
protein engineering to optimize the Cas-Transposon system, we should also consider alternative 
transposases, alternative DNA-binding domains, such as dCas9 homologs from other species 
with smaller sizes and/or alternate sequence target sites, and alternative peptide linkers 
connecting the two domains. By using transposases with different insertion sites and DNA-binding 
domains with alternate PAM specificities and adjusting the linker length, the Cas-Transposon 
protein may be tailored for optimal function in different organisms with different GC contents and 
distributions of PAMs and insertion sites. Although the Tn5-dCas9 transposase described here 
did not produce site-specific transposon insertions, the gRNAs we tested were not optimized for 
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Tn5 insertion sites, and the protein itself was missing one canonical hyperactive mutation 
(M56A)131, so there may be room for improvement of the Tn5-dCas9 transposase along with 
mariner-dCas9 fusions. If optimization of the Cas-Transposon technology is successful, the 
platform would enable a novel modality of site-specific DNA insertion for targeted genome editing.  
 
2.5 MATERIALS AND METHODS 
 
Measurement of fluorescence knockdown by Himar1C9-dCas9 fusion proteins in E. coli: We 
measured knockdown of mCherry in MG1655 galK::mCherry-specR E. coli and knockdown of 
GFP in s17 E. coli containing the pTarget plasmid. Each strain had a tet-inducible expression 
vector for Himar1C9-dCas9 or dCas9, which also contained up to constitutively expressed 2 
gRNAs. Overnight cultures were diluted 1:40 into media containing various concentrations of 
anhydrotetracycline (ATc) to induce HdCas9 expression. 200 uL of each induced culture was 
grown in 96-well plates at 37C with shaking on a BioTek plate reader. Measurements of OD600 
and fluorescence were taken every 5-10 minutes for 12 hours. Fluorescence measurements were 
reported as F/OD600. 
 
Measurement of transposase activity in E. coli: Himar1C9-L2-dCas9 and Himar1C9 were 
expressed in MG1655 E. coli from a tet-inducible expression vector. These MG1655 strains were 
conjugated with diaminopimelic acid-auxotrophic donor strain EcGT2 (s17 asd::mCherry-specR), 
which contained transposon donor plasmid pHimar2. Donor and recipient cultures were grown 
overnight at 37C; donors were grown in LB media with DAP (50 uM) and kanamycin (50 ug/mL), 
and recipients were grown in LB with chloramphenicol (20 ug/mL). 100 uL of donor and recipient 
were diluted into 3 mL fresh media +/- 2 uM ATc and grown for 6 hours at 37C. 1 mL each of 
donor and recipient cultures were centrifuged and resuspended twice in PBS to wash the cells 
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and then centrifuged to form a pellet. Donor and recipient pellets were combined in 50 uL PBS 
and dropped onto LB agar with 50 uM DAP +/- 2 uM ATc. The cell droplets were dried at room 
temperature, and the conjugations were incubated for 10 hours at 30C. The resulting cells were 
scraped off, homogenized by pipetting, and plated on nonselective LB agar plates and LB + 
carbenicillin (50 ug/mL) plates to select for MG1655 cells with a transposon. Transposition rates 
were measured as the ratio of carbenicillin-resistant CFUs to total CFUs. 
 
Purification of Himar-dCas9 protein for in vitro transposition assays: His-tagged Himar-dCas9 
(HdCas9) was purified by nickel affinity chromatography. The Himar transposase gene was 
obtained from plasmid pSAM-BT, and the dCas9 gene sequence was obtained from pdCas9-
bacteria, a gift from Stanley Qi (Addgene plasmid #44249). Linker sequences were obtained from 
previously described FokI-dCas9 fusions119 and synthesized as gBlocks (Integrated DNA 
Technologies). Himar-dCas9 fusion constructs were cloned into a C-terminal 6xHis-tagged pET 
expression vector using NEBuilder® HiFi DNA Assembly Master Mix (New England Biolabs). 
pET-Himar-dCas9 vectors were electroporated into competent Rosetta2 cells (Novagen); 
transformants were selected on chloramphenicol 34 ug/uL and carbenicillin 50 ug/uL. 
 Rosetta2 protein expression strains were inoculated from a single colony into 4 mL of LB 
with chloramphenicol 34 ug/uL and carbenicillin 50 ug/uL and grown to saturation overnight at 
37C with shaking. 1 mL of saturated culture was diluted 1:100 into 100 mL of fresh media and 
grown to OD 0.6-0.8 at 37C with shaking. 0.2 mM of IPTG was added to the culture, and the flask 
was moved to 18C and incubated overnight (16-18 hours) with shaking. The induced overnight 
culture was chilled on ice and centrifuged at 4C, 7197xg for 5 minutes to pellet the cells. The cell 
pellet was resuspended in 5 mL of Protein Resuspension Buffer (PRB) inside a 50 mL conical 
tube, which was kept chilled in an ice water bath. The cells were lysed by sonication using a 
Qsonica sonicator at 40% power for a total of 120 seconds in 20 second/20 second on/off 
intervals. The cell suspension was mixed by pipetting, and the sonication cycle was repeated to 
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ensure complete lysis. The cell lysate was centrifuged at 7197 x g for 10 minutes at 4C to pellet 
cell debris. The cleared cell lysate was collected. 
To equilibrate the nickel affinity resin, 1 mL of Ni-NTA Agarose (Qiagen) was added to a 
15 mL polypropylene gravity flow column (Qiagen), storage buffer was allowed to flow through by 
gravity, and the resin was washed in 5 mL of PRB and drained. The cleared cell lysate was added 
to the column and incubated at 4C on a rotating platform for 30 minutes. The cell lysate was 
flowed through, and the nickel resin was washed with 25 mL PWB in 5 mL increments. The protein 
was then eluted with PEB in 5 fractions of 0.5 mL each. Most protein eluted in fractions 2-4. Each 
elution fraction was analyzed by running an SDS-PAGE gel to check for the presence of the 
protein. 
Elution fractions 2-4 were combined and dialyzed overnight in 500 mL of DB1 at 4C using 
10K MWCO Slide-A-Lyzer™ Dialysis Cassettes (Thermo Fisher). The protein was dialyzed again 
in 500 mL DB2 for 6 hours. The dialyzed protein was quantified with the Qubit Protein Assay Kit 
(Thermo Fisher) and divided into single-use aliquots. Protein aliquots were snap frozen in dry ice 
and ethanol and stored at -80C. Tn5-dCas9 was purified in the same manner. 
 
In vitro transposition reaction setup: Each in vitro HdCas9 transposition reaction was performed 
in a buffer consisting of 10% glycerol, 2 mM dithiothreitol, 250 ug/mL of bovine serum albumin, 
25 mM HEPES (pH 7.9), 100 mM NaCl, and 10 mM MgCl2. Reactions contained 0-5 nM of 
transposon donor and target plasmids, 0-100 nM of transposase/gRNA complexes, and 0-800 ng 
of background E. coli genomic DNA in a final volume of 20 uL. 
 Plasmid DNA was purified using the ZymoPureII midiprep kit (Zymo Research) and 
purified again using the Zymo Clean and Concentrator-25 (Zymo Research) kit to remove all 
traces of RNAse. Genomic DNA was purified from E. coli using the MasterPure Gram Positive 
DNA Purification Kit (Epicentre) and purified again using the Zymo Clean and Concentrator-25 
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kit. All DNAs were eluted into nuclease-free water. DNA concentrations were quantified using the 
Qubit dsDNA BR Assay kit (Invitrogen). 
 gRNAs for in vitro experiments were synthesized and purified using the GeneArt™ 
Precision gRNA Synthesis Kit (Invitrogen) according to manufacturer’s instructions. gRNA 
concentrations were measured using the Qubit RNA HS Assay Kit. gRNAs were aliquoted into 
single-use tubes, flash frozen in dry ice and ethanol, and stored at -80C until usage. 
Frozen aliquots of transposase protein and gRNAs were thawed on ice. The protein was 
diluted to 20x final concentration in DB2 buffer, and gRNAs were diluted to the same molarity in 
nuclease-free water. The diluted protein and gRNA were mixed in equal volumes and incubated 
at room temperature for 15 minutes. Transposon donor DNA, target plasmid DNA, and 
background DNA (if applicable) were mixed on ice with 10 uL of a 2x buffer master mix and water 
to reach a volume of 18 uL; 2 uL of the protein/gRNA mixture was added last to the reaction. In 
reactions where the transposase/gRNA complex was preloaded onto the target plasmid, the 
target plasmid was mixed with protein and gRNA and incubated at 30C for 10 minutes, and the 
donor DNA was added last. Transposition reactions were incubated for 3-72 hours at 30-37C and 
then heat-inactivated at 75C for 20 minutes. Transposition products were purified using magnetic 
beads, eluted in 45 uL of nuclease-free water, and stored at -20C. 
In vitro Tn5-dCas9 transposition reactions were set up similarly, except the reaction buffer 
contained 50 mM Tris-acetate (pH 7.5), 150 mM potassium acetate, 10 mM magnesium acetate, 
and 4 mM spermidine. Purified Tn5-dCas9 protein was diluted in 50% glycerol, 50 mM Tris-HCl 
(pH 7.6), 100 mM KCl, and 1 mM DTT. 
  
 
qPCR assay for site-specific insertions: For each reaction, 2 qPCRs were performed to obtain the 
measure of the relative Cq: one PCR amplifying transposon-target plasmid junctions, and another 
PCR amplifying the target plasmid backbone to normalize for template DNA input across samples. 
Relative Cq measurements shown in this study are the differences between these two Cq values. 
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For in vitro Himar transposition into pGT-B1, primers p433 and p415 were used for junction PCRs, 
and primers p828 and p829 were used for control PCRs. For Tn5 in vitro transposition into pGT-
B1, primers p858 and p859 were used for junction PCRs. For in vitro Himar transposition into 
pTarget or pZE41-eGFP, primers p898 and p415 were used for junction PCRs and primers p899 
and p900 were used for control PCRs. All qPCR primers used in this study are listed in Table 3.  
PCR reactions contained 1 uL each of 10 uM forward and reverse primers, 1 uL of purified 
transposition products as template DNA, 7 uL water, and 10 uL of Q5 2X Master Mix (NEB) + 
SYBR Green. Reactions were thermocycled using a Bio-Rad C1000 touch qPCR machine for 1 
minute at 98C, followed by 35 cycles of 98C denaturation for 10 seconds, 67-68C annealing for 
15 seconds, and 72C extension for 2 minutes. PCR products were quantified by SYBR Green 
fluorescence and qualitatively analyzed for specificity on agarose DNA gels.  
 
Transformation assay for in vitro transposition reaction products: 5uL purified DNA from an in vitro 
transposition reaction was mixed with 45 uL distilled water and chilled on ice. 10 uL of thawed 
MegaX electrocompetent E. coli (Invitrogen) was added and pipetted up and down gently until 
just mixed. The mixture was transferred to a 0.1 cm gap electroporation cuvette (BioRad) and 
electroporated at a voltage of 1.8 kV. The cells were immediately recovered in 1 mL of SOC and 
incubated with shaking at 37C for 90 minutes. The cells were plated on antibiotic selection plates 
containing chloramphenicol 34 ug/mL to select for target plasmids containing transposons, and 
on plates with carbenicillin 50 ug/mL to measure the electroporation efficiency of target plasmids. 
The efficiency of transposition was measured as the ratio of chlor-resistant transformants to carb-
resistant transformants. To assess specificity of inserted transposons, we performed colony PCR 
on transformants using the primer set p433/p415 with KAPA2G Robust HotStart ReadyMix (Kapa 





Transposon sequencing library preparation: Transposon junctions were PCR amplified from in 
vitro transposition reactions using primer sets p923/p433 and p923/p922, using Q5 HiFi 2x Master 
Mix (NEB) + SYBR Green. Reactions were thermocycled using a Bio-Rad C1000 touch qPCR 
machine for 1 minute at 98C, followed by cycles of 98C denaturation for 10 seconds, 68C 
annealing for 15 seconds, and 72C extension for 2 minutes. PCR reactions were stopped in late 
exponential phase in order to avoid oversaturation of PCR products. PCR products were purified 
using magnetic beads, and 100-200 ng of DNA per sample was digested with MmeI (NEB) for 1 
hour in a reaction volume of 40 uL. The MmeI digestion products were purified using Dynabeads 
M-270 Streptavidin beads (ThermoFisher) according to manufacturer instructions. The digested 
transposon ends, bound to magnetic Dynabeads, were mixed with 1 ug sequencing adapter DNA 
(see next section), 1 uL T4 DNA ligase, and T4 DNA ligase buffer in a total reaction volume of 50 
uL. The ligation reactions were incubated at room temperature (23C) for 1 hour; the ligase enzyme 
and excess sequencing adapter were removed by washing the beads according to Dynabead 
manufacturer instructions. Dynabeads were resuspended in 40 uL of water.  
2 uL of the Dynabeads were used as template for the final PCR using barcoded P5 and 
P7 primers and Q5 HiFi 2x Master Mix (NEB) + SYBR Green. Reactions were thermocycled using 
a Bio-Rad C1000 touch qPCR machine for 1 minute at 98C, followed by cycles of 98C 
denaturation for 10 seconds, 67C annealing for 15 seconds, and 72C extension for 20 seconds. 
PCR reactions were stopped in late exponential phase in order to avoid oversaturation of PCR 
products. Equal amounts of DNA from all PCR reactions were combined into one sequencing 
library, which was purified and size-selected for 145 bp products using the Select-a-Size Clean 
and Concentrator kit (Zymo). The library was quantified with the Qubit dsDNA HS Assay Kit 
(Invitrogen) and combined in a 7:3 ratio with PhiX sequencing control DNA. The library was 
sequenced using a MiSeq V2 50 Cycle kit (Illumina) with custom read 1 and index 1 primers 
spiked into the standard read 1 and index 1 wells. Reads were mapped to the pGT-B1 plasmid 




Construction of sequencing adapter by annealing: Oligonucleotides Adapter_T and Adapter_B 
were diluted to 100 uM in nuclease-free water. 10 uL of each oligo was mixed with 2.5 uL water 
and 2.5 uL of 10x Annealing Buffer. Using a thermocycler, the mixture was heated to 95C and 
slowly cooled at 0.1C/second to 4C to yield 25 uL of 40 uM sequencing adapter. The adapter was 
stored at -20C until ready for use. 
 
In vivo assays for transposition into a target plasmid: s17 E. coli were transformed with pTarget-
GFP and pHdCas9-gRNA plasmids by electroporation; transformants were selected on LB with 
spectinomycin (240 ug/mL) and carbenicillin (50 ug/mL). E. coli containing these two plasmids 
were grown from a single colony to mid-log phase in liquid selective media, electroporated with 
130 ng pHimar6 transposon donor plasmid DNA, and recovered in 1 mL LB for 1 hour at 37C with 
shaking post-electroporation. 100 uL of a 10^-3 dilution of the transformation was plated on LB 
agar plates with spectinomycin (240 ug/mL), carbenicillin (50 ug/mL), chloramphenicol (20 
ug/mL), MgCl2 (20 mM), and ATC (0-2 ng/mL). Plates were grown at 37C for 16 hours. Between 
10^3 and 10^4 colonies were scraped off each plate into 2 mL PBS and homogenized by pipetting. 
500 uL of the cells were miniprepped using the QIAprep kit (Qiagen). 
 Minipreps from each transformation were evaluated by qPCR for transposon junctions and 
by a transformation assay. qPCR assays for transposon-target plasmid junctions were performed 
as described above, using primers p898 and p415 and 10 ng of miniprep DNA as PCR template. 
The control PCR to normalize for DNA input was performed with primers p899 and p900. In 
transformations, 150 ng of plasmid DNA was electroporated into 10 uL of MegaX 
electrocompetent cells diluted in 50 uL of ice-cold distilled water. Cells were immediately 
recovered in 1 mL of LB and incubated with shaking at 37C for 90 minutes. The cells were plated 
on LB agar with chloramphenicol (20 ug/mL) and spectinomycin (60 ug/mL) to select for target 
plasmids containing a Himar transposon. We performed colony PCR using the primer set 
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p898/p415 with KAPA2G Robust HotStart ReadyMix (Kapa Biosystems) to amplify Himar-target 
plasmid junctions, which were analyzed by Sanger sequencing. 
 
Generation of CHO cell lines for transposition assays: CHO cells were cultured in Ham’s F-12K 
(Kaighn’s) Medium (ThermoFisher) with 10% fetal bovine serum and 1% penicillin-streptomycin. 
The eGFP+ CHO cell line was generated by transfection of plasmids pcDNA5/FRT/Hyg-eGFP  
and pOG44 into the Flp-In™-CHO cell line (ThermoFisher) followed by selection in media with 
hygromycin (500 ug/mL). An eGFP-, mCherry+, puromycin-resistant site-specific transposition 
positive control cell line was generated by transfection of plasmids pcDNA5/FRT/Hyg-Himar and 
pOG44 into the Flp-In™-CHO cell line followed by selection in media with puromycin (10 ug/mL). 
Transfections were performed on cells at 70% confluence in 6-well plates using 12 uL of 
Lipofectamine 2000 and 1000 ng of each plasmid. Antibiotic selection was initiated 48 hours after 
transfection. Polyclonal transfected cells were trypsinized and passaged for use in subsequent 
experiments. 
 
In vivo transposition assays in mammalian cells: The eGFP+ CHO cell line was transfected with 
a pHP transposon donor plasmid and the pHdCas9-mammalian expression plasmid. 
Transfections were performed on cells at 70% confluence in 6-well plates using 12 uL of 
Lipofectamine 2000 and 1250 ng of each plasmid. In the transposition negative control, the pHP-
M1-M2 plasmid was transfected without the pHdCas9-mammalian plasmid. Transfection 
efficiencies were 40-70% based on flow cytometry measurements of mCherry expression in cells 
24 hours post-transfection of control pHP-on plasmids. Antibiotic selection with puromycin (10 
ug/mL) was initiated 48 hours after transfection. Cells resulting from each transfection were 
trypsinized after 9 days of antibiotic selection, and the whole volume was transferred into a single 
well on a 12-well plate and grown for 4 more days in puromycin media. During the 13 days of 
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antibiotic selection, media was changed every 24 hours. Post-selection cells were trypsinized and 
diluted 1:5 in fresh media and analyzed for GFP and mCherry fluorescence on a Guava easyCyte 
flow cytometer (Millipore). Gates for mCherry and GFP fluorescence were set using mCherry-
/eGFP- FLP-In CHO cells, mCherry-/eGFP+ CHO cells, and mCherry+/eGFP- transposition 
positive control CHO cells.  
Genomic DNA from trypsinized cells was extracted using the Wizard Genomic DNA 
Purification Kit (Promega) for PCR analysis. qPCR for transposon-gDNA junctions was performed 
as described above, using primers p933 and p946. The control PCR to normalize for DNA input 




Protein Resuspension Buffer (PRB): 20 mM Tris-HCl pH 8.0, 10 mM imidazole, 300 mM NaCl, 
10% v/v glycerol. 1 tablet of cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail (Roche) 
was dissolved in 10 mL of buffer immediately before use. 
  
Protein Wash Buffer (PWB): 20 mM Tris-HCl pH 8.0, 30 mM imidazole, 500 mM NaCl, 10% v/v 
glycerol 
  
Protein Elution Buffer (PEB): 20 mM Tris-HCl pH 8.0, 500 mM imidazole, 500 mM NaCl, 10% 
v/v glycerol 
  





Dialysis Buffer 2 (DB2): 25 mM Tris-HCl pH 7.6, 200 mM KCl, 10 mM MgCl2, 0.5 mM DTT, 10% 
v/v glycerol 
 




We thank Saeed Tavazoie, Alexandra Ketcham, and Anupama Khare for guidance on transposon 
sequencing. Eric Greene, Justin Steinfeld, and Chu Jian Ma provided materials and guidance on 
in vitro protein expression and purification. We thank members of the Wang lab for helpful 
scientific discussions and feedback. Ross McBee, Andrew Kaufman, and Liyuan Liu assisted with 
mammalian cell transfections. H.H.W. acknowledges funding from ONR (N00014-15-1-2704), 
DARPA (W911NF-15-2-0065), NIH (1DP5OD009172), and Burroughs Wellcome PATH 
(1016691). S.P.C. is supported by a NIDDK F30 fellowship (F30 DK111145-01A1) and a NIH 
MSTP training grant (NIH T32GM007367). 
 
AUTHOR CONTRIBUTIONS 
S.P.C. and H.H.W. designed the study. S.P.C. performed the experiments. S.P.C. and H.H.W. 
analyzed the data and wrote the manuscript.  
 
COMPETING FINANCIAL INTERESTS  
A provisional patent application has been filed by The Trustees of Columbia University in the City 






Figure 2.1. Schematics of in vitro Cas-Transposon test system. (a) Overview of Himar1-
dCas9 protein function. The Himar1-dCas9 fusion protein is guided to the target insertion site by 
a gRNA, where it is tethered by the dCas9 domain. The Himar1 domain dimerizes with that of 
another fusion protein to cut-and-paste a Himar transposon into the target gene, which is knocked 
out in the same step. (b) Implementation of Cas-Transposon system in vitro. Transposon donor 
and target plasmids are mixed with purified protein and gRNA. Post-transposition target plasmids 
are analyzed by PCR for plasmid/transposon junctions, transformation and colony analysis, and 
transposon sequencing. (c) Schematic of target plasmid/transposon junction PCR. The PCR is 
performed using primer 1, which binds the transposon, and primer 2, which binds the target 
plasmid. Site-specific transposition should result in an enrichment for a PCR product 






Figure 2.2. HdCas9 specificity is dependent on gRNA spacing and target site. (a) Illustration 
of gRNA strand orientation and spacings to TA insertion site. (b) PCR analysis of 
transposon/target junctions from in vitro reactions containing 30 nM HdCas9/gRNA complex, 2.27 
nM transposon donor DNA, and 2.27 nM target DNA. Reactions (n=3) were run using gRNAs with 
spacings between 5 and 18 bp from the TA insertion site. Non-targeting gRNA (gRNA 5), no 
gRNA, and no transposase controls were also performed. Red arrows indicate expected site-
specific PCR products for each gRNA. Error bars indicate standard deviation. (c) Transposon 
sequencing results for reactions with no gRNAs (left, gray, n=4) or with gRNAs 4 (blue, n=3), 8 
(orange, n=3), 12 (green, n=3), or 5 (black, n=3). The baseline random distribution of transposons 






Figure 2.3. HdCas9-mediated site-specific transposition is robust to changes in 
ribonucleoprotein complex and DNA concentration. (a) PCR analysis of transposition 
reactions (n=3) using varying levels of HdCas-gRNA 4 complexes. Reactions were performed for 
3 hours at 30C with 5 nM of donor and recipient plasmid DNA. (b) Transformation assay to 
measure transposition rates in reactions using varying levels of HdCas-gRNA 4 complexes. 
Reactions were performed for 3 hours at 30C with 5 nM of donor and recipient plasmid DNA. 3 
independent reactions were performed per concentration, with 1-2 transformation replicates per 
reaction. (c) PCR analysis of transposition reactions (n=3) using varying levels of donor plasmid 
DNA. Reactions were performed for 3 hours at 30C with 5 nM of recipient plasmid DNA and 30 
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nM HdCas-gRNA 4 complex. (d) PCR analysis of transposition reactions (n=3) using varying 
levels of recipient plasmid DNA. Reactions were performed for 3 hours at 30C with 0.5 nM of 
donor plasmid DNA and 30 nM HdCas-gRNA 4 complex. (e) PCR analysis of transposition 
reactions (n=3) performed for different lengths of time, in the presence or absence of background 
non-specific DNA. Reactions were performed at 37C with 1 nM of recipient plasmid DNA, 1 nM 
of donor plasmid DNA, and 100 nM HdCas-gRNA 4 complex. Background E. coli genomic DNA 
was present at 10x the mass of recipient plasmid DNA. (f) qPCR measurement of transposition 
efficiency in reactions shown in panel (e). n=3 for each reaction condition. 
In all panels, red arrows indicate the expected PCR product for gRNA 4, and error bars indicate 







Figure 2.4. HdCas9 performs site-specific transpositions into plasmids in E. coli. (a) Three 
plasmids were transformed into S17 E. coli to create a testbed for HdCas9 transposition specificity 
in vivo. Post-transposition plasmids were extracted from the bacteria and analyzed by PCR and 
by transformation into competent E. coli with Sanger sequencing of plasmids from individual 
colonies. (b) HdCas9 knocks down GFP expression from the pTarget plasmid in vivo in E. coli 
with gRNA 1, which targets the non-template strand (N) of the GFP gene. HdCas9 does not knock 
down GFP fluorescence when expressed with a gRNA complementing the template strand (T) or 
with a non-targeting gRNA (NT) or no gRNA. n=2 per gRNA and ATC concentration. (c) PCR 
assay of in vitro transposition reactions using donor plasmid pHimar6 and recipient plasmid 
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pTarget. 2.27 nM of donor and recipient plasmids along with 30 nM HdCas9-gRNA complex were 
incubated for 3 hours at 30C. Expected PCR products of targeted insertions are shown with red 
arrows. (d) PCR analysis of pTarget-transposon junctions resulting from in vivo transposition in 
bacteria. 3/5 of gRNA 1 PCR products show enrichment for the targeted insertion product. 
Transpositions A, B, C, and D with gRNA 1 were also analyzed by transformation and colony 
analysis. (e) Plasmid pools from 4 independent in vivo transposition experiments using gRNA 1 
were transformed into E. coli, and the resultant colonies were analyzed by PCR and Sanger 
sequencing. The pie charts show the number of colonies containing on-target and off-target 







Supplementary Figure S2.1. Himar1-dCas9 fusions retain DNA binding and transposition 
functionalities. (a) dCas9 and Himar1C9-L2-dCas9 were expressed in MG1655 galK::mCherry-
specR E. coli with gRNAs 5 and 16. Protein expression was induced with 2 uM ATC. Both proteins 
decreased mCherry expression, indicating that the Himar1C9-L2-dCas9 protein bound the 
mCherry gene specified by the gRNAs and blocked transcription. (b) Himar1C9 and Himar1C9-
L2-dCas9 were measured for transposition activity in an E. coli conjugation assay. Both Himar1C9 







Supplementary Figure S2.2. Workflow for transposon sequencing library preparation from 
in vitro transposition reactions. To selectively isolate transposons that had become integrated 
into recipient plasmid for sequencing, we performed PCRs using a biotinylated primer 
complementing the transposon end and reverse primers complementing the recipient plasmid. 
Two PCRs using reverse primers on opposite sides of the recipient plasmid were performed to 
account for PCR size bias during amplification of transposon junction products. PCR products 
were isolated using streptavidin beads and digested with MmeI to isolate transposon ends with a 
~17bp overhang. A sequencing adapter was ligated, and the DNA was PCR-amplified to add 
barcoded Illumina adapters. The resulting libraries from each PCR were sequenced 
independently and normalized for total reads, and the normalized libraries were averaged to 






Supplementary Figure S2.3. PCR assay shows no evidence of in vitro targeted 
transposition using a Tn5-dCas9 fusion protein. Purified Tn5-dCas9-gRNA complexes (30 
nM) with hyperactive E54K and L372P mutations were incubated with a Tn5 transposon donor 
plasmid (2.27 nM) and recipient vector pGT-B1 (2.27 nM) for 3 hours at 37C. Red arrows indicate 







Supplementary Figure S2.4. In vitro assay to analyze transposition by HdCas9 with 2 
gRNAs. (a) In vitro reactions containing 2 gRNAs were set up in 2 configurations to determine 
whether paired HdCas9 proteins bound at the same TA site would improve Himar dimerization 
and transposition activity, compared with HdCas9 proteins all bound individually to target 
plasmids. HdCas9 was first incubated with either gRNA A (red) or gRNA B (blue), and then the 
HdCas9-gRNA complexes were preloaded onto target plasmids as pairs (left) or as single 
complexes (right). Preloaded target plasmid-HdCas9-gRNA complexes were then mixed with 
transposon donor plasmids. The total final concentration of each protein-gRNA complex was 2.5 
nM, and final concentrations of donor and target DNAs were 5 nM. (b) PCR analysis of 
transposition by HdCas9 with a single gRNA (left) or HdCas9 with 2 gRNAs (right), preloaded in 
separated (S) or paired configurations (P). Red arrows indicate expected PCR products for each 
reaction. (c) qPCR analysis of transposition by HdCas9 with a single gRNA, HdCas9 with 2 
gRNAs (in a separated configuration), and HdCas9 with 2 gRNAs (in a paired configuration). n = 





Supplementary Figure S2.5. HdCas9 performs in vitro site-specific transposition in the 
presence of background DNA. (a) PCR analysis of transposition reactions (n=3-6) with varying 
levels of background E. coli genomic DNA. Reactions were performed for 3 hours at 30C with 1 
nM of target plasmid DNA, 1 nM of donor plasmid DNA, and 10 nM HdCas-gRNA 4 complex. 
Ratios of background to target plasmid DNA are by mass. (b) PCR analysis of transposition 
reactions (n=3) performed for different lengths of time, in the presence or absence of background 
non-specific DNA. Reactions were performed at 37C with 1 nM of recipient plasmid DNA, 1 nM 
of donor plasmid DNA, and 10 nM HdCas-gRNA 4 complex. Background E. coli genomic DNA 
was present at 10x the mass of recipient plasmid DNA. (c) qPCR measurement of transposition 







Supplementary Figure S2.6. HdCas9 was not observed to target transposon insertions into 
a genomic locus in Chinese hamster ovary (CHO) cells. (a) eGFP+ CHO cells were 
transfected with an expression vector for HdCas9 and a transposon donor vector with expression 
constructs for gRNAs targeting the eGFP gene. The transposon contained a promoterless 
puromycin resistance gene and mCherry gene, which would both be expressed if the transposon 
integrated into the correct target site on eGFP. Puromycin-resistant cells resulting from 
transfection were analyzed by flow cytometry and PCR for transposon-target junctions. (b) PCR 
assay of in vitro transposition reactions with HdCas9 and eGFP-targeting gRNAs, using donor 
plasmid pHimar6 and recipient plasmid pZE41-eGFP. 2.27 nM of donor and recipient plasmids 
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along with 30 nM HdCas9-gRNA complex were incubated for 3 hours at 37C. Expected PCR 
products of targeted insertions are shown with red arrows. gRNAs M1 and M2 target the same 
insertion site. (c) Representative flow cytometry dot plots for transfected cells after 13 days of 
puromycin selection. A transposase-free control transfection did not produce viable cells and was 
not analyzed by flow cytometry. (d) Upon flow cytometry, 5-15% of cells in some transfections 
were GFP-negative. (e) PCR for eGFP-transposon junctions in genomic DNA resulting from in 
vivo transposition did not show evidence of site-specific transposition. The positive control PCR 
used a plasmid with the transposon cloned into the target site of eGFP as template. The red arrow 
indicates the expected size of the targeted transposition product, which is the same for gRNAs 




Table 2.1. Plasmids used in this study. 
 




Selection Features Purpose 




pGT-B1 pBBR1 6235 carb constitutive 
sfGFP gene 
target plasmid for in 
vitro assays 






donor plasmid for in 
vitro and E. coli in 
vivo assays 
pTarget ColE1 3237 spec constitutive 
sfGFP gene 
target plasmid for E. 
coli in vivo assays 
pZE41-eGFP ColE1 3154 spec eGFP on pL-tetO 
promoter 
target plasmid for in 
vitro testing of 
mammalian gRNAs 







vector for HdCas9 
and gRNA 1 
pHdCas9-gRNA1-
gRNA2 





1 and gRNA 2 
bacterial expression 
vector for HdCas9, 
gRNA1, and gRNA 2 







vector for HdCas9 
and gRNA 4 







vector for HdCas9 
and gRNA 5 




vector for HdCas9 




vector for HdCas9 
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from U6 promoter 
Himar transposon 
donor plasmid for 
mammalian cells;  
expression vector for 
gRNA M1 





from U6 promoter 
Himar transposon 
donor plasmid for 
mammalian cells;  
expression vector for 
gRNA M2 








donor plasmid for 
mammalian cells;  
expression vector for 
gRNAs M1 and M2 





cloning site for 
gRNAs can also 
be expressed as 
a gRNA from U6 
promoter 
Himar transposon 
donor plasmid for 
mammalian cells; 
expression vector for 
non-targeting gRNA 
M3; Golden Gate 
cloning vector for 
gRNAs 





donor plasmid for 
mammalian cells 


































into FLP-in cell 













create positive control 
FLP-in cell line 
containing site-
















TA site (bp) 
1 GTCGTTACCAGAGTCGGCCA sfGFP N 8 
2 TCAGTGCTTTGCTCGTTATC sfGFP T 7 
3 CGTTCCTGCACATAGCCTTC sfGFP N 13 
4 CGGCACGTACAAAACGCGTG sfGFP T 8 
5 GTCGGCGGGGTGCTTCACGT mCherry N 10 
7 ACCAGAGTCGGCCAAGGTAC sfGFP N 14 
8 CTGCACATAGCCTTCCGGCA sfGFP N 18 
9 CAATGCCTTTCAGCTCAATG sfGFP N 5 
10 CAGCTCAATGCGGTTTACCA sfGFP N 15 
11 GTAAACCGCATTGAGCTGAA sfGFP T 6 
12 CAATATCCTGGGCCATAAGC sfGFP T 11 
13 AGAACAGGACCATCACCGAT sfGFP N 17 
14 GTGCTCAGATAGTGATTGTC sfGFP N 16 
15 GAACTGGATGGTGATGTCAA sfGFP T 9 
16 CCTTCCCCGAGGGCTTCAAG mCherry T 12 
18 ACGCGATCACATGGTTCTGC sfGFP T 17 
M1 GACCAGGATGGGCACCACCC eGFP N 17 
M2 CAAGTTCAGCGTGTCCGGCG eGFP T 9 
M3 GAGACGATTAATGCGTCTC - - - 
 
T indicates that the gRNA is complementary to the Template strand of the gene, while N 
indicates that the gRNA complements the Non-template strand. gRNAs that target the same TA 
insertion site are labeled with the same color. gRNAs 11, 13, and 15 all target different sites 




Table 2.3. Oligonucleotides used in this study. 
 
Name Sequence (5' -> 3') Target Tm ( C ) Function 
p433 CGCTTACAATTTC
CATTCGCCATTC 










pGT-B1 70 Control qPCR  for pGT-B1 
p829 CAGTCCAGAGAA
ATCGGCATTCA 
















    Anneal to make Y-shapted 




    Anneal to make Y-shapted 









73 Add barcode & P5 sequence to 










73 Add barcode & P5 sequence to 










73 Add barcode & P5 sequence to 










73 Add barcode & P5 sequence to 










73 Add barcode & P5 sequence to 












73 Add barcode & P5 sequence to 


















ColE1 oriR 67 qPCR  for Himar transposon-
plasmid junctions in  pTarget-




ColE1 oriR 67 Control qPCR for pTarget-
sfGFP and pZE41-eGFP 
p900 TCCCTTAACGTG
AGTTTTCGTTCC 
ColE1 oriR 67 Control qPCR for pTarget-




mCherry 67 Control qPCR for Himar 




mCherry 68 Control qPCR for Himar 






67 qPCR for Himar transposon-







68 qPCR for Himar transposon-
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Engineering microbial communities in open environments remains challenging. Here, we 
describe a platform to identify and modify genetically tractable mammalian microbiota by 
engineering community-wide horizontal gene transfer events in situ. With this approach, we 
demonstrate that diverse taxa in the murine gut microbiome can be modified directly with a desired 
genetic payload. In situ microbiome engineering in living animals enables introduction of novel 





3.2 MAIN TEXT 
 
In nature, microbes live in open, dynamic and complex habitats that can be difficult, if not 
impossible, to recapitulate in a laboratory setting. Recent advances in deep sequencing have shed 
light on the vast microbial diversity that exists in many environments, including the mammalian gut. 
However, our ability to genetically access and alter these microbiomes remains limited despite 
advances in culturomics and synthetic biology81, 99, 133, 134. While genetic intractability is often 
attributed to host immunity such as restriction-methylation135 or CRISPR-Cas processes136, a myriad 
of other factors (e.g., DNA transformation, growth state, fitness  burden) may also influence gene 
transfer potential137. The inability to genetically alter a bacterium greatly limits our basic 
understanding of the organism and its biotechnological potential. To overcome these challenges, 
we devised an approach, Metagenomic Alteration of Gut microbiome by In situ Conjugation 
(MAGIC), to genetically modify gut microbiota in their native habitat by engineering the mobilome—
the  repertoire of mobile genetic elements that permeate the gut microbiome. Implementing MAGIC 
directly on a complex gut microbiome in its natural habitat enables genetic modification of diverse 
microbes and development of new modifiable microbial chasses for synthetic applications (Figure 
3.1a).  
We sought to utilize the mammalian gut as a testbed for MAGIC because it harbors a diverse 
microbial community that also plays a key functional role in host physiology4.  We constructed a 
laboratory Escherichia coli donor strain that can deliver a genetic payload into target recipients by 
broad host-range bacterial conjugation (Figure 3.1b). The IncPα-family RP4 conjugation system138, 
which can efficiently conjugate into both Gram-positive and Gram-negative cells, was integrated into 
the EcGT1 donor genome along with a constitutively expressing mCherry-specR cassette 
(∆galK::mCherry-specR). To strengthen biocontainment of the donor and to facilitate in vitro 
selection of recipients, an alternative strain EcGT2 (∆asd::mCherry-specR) was generated to be 
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auxotrophic for the essential cell wall component diaminopimelic acid (DAP), thus requiring DAP 
supplementation in the growth media139. 
We developed a modular suite of mobile plasmids (pGT) that featured replicative origins with 
narrow to broad host-ranges, a RP4 transfer origin, a selectable marker, and the desired genetic 
payload (Suppl. Tables 3.1-3.3, Suppl. Figure S3.1). A broad host-range Himar transposon system 
was also utilized for delivering integrative payloads. As a demonstration of the system, we used a 
dual-reporter payload harboring a green fluorescent protein (GFP) and an antibiotic resistance gene 
(AbR). The use of Fluorescence Activated Cell Sorting (FACS) combined with 16S metagenomic 
analysis enables identification of successfully modified recipients or transconjugants, which can then 
be readily isolated on antibiotic selective plates. This multi-pronged strategy can increase the 
diversity of genetically tractable microbiota that can be captured.  We first validated and optimized 
MAGIC protocols in vitro by assessing the gating stringency of FACS with control spike-ins of GFP-
tagged bacteria into a complex sample community (Suppl. Figure S3.2). Subsequently, in vitro 
conjugations with defined recipient species (Suppl. Figure S3.3) and live bacterial communities 
extracted from mouse feces (Suppl. Figure S3.4) demonstrated the transfer of the payload from 
donors to recipients to yield GFP+ transconjugants that could be enriched by FACS (Suppl. Figure 
S3.5), which were confirmed by fluorescence microscopy (Suppl. Figure S3.6). 16S rRNA 
sequencing of FACS-enriched transconjugant populations revealed a diverse range of recipient 
bacteria (Suppl. Figure S3.7). 
Since the gut microbiome can vary widely between hosts and can change due to dietary or 
other environmental variables, we explored the possibility of implementing MAGIC in vivo, directly 
in the native gut microbiome of an animal. We hypothesized that different groups of microbiota may 
be modified by using a library of pGT vectors that exhibit a range of gene expression levels and 
plasmid replication elements suitable for different gut bacteria. Libraries of pGT vectors (pGT-L1 
to pGT-L6) were generated by modularly permuting pGT parts, including regulatory sequences of 
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varying activity, payload selectable genes (bla, catP, tetQ), transposon elements (Himar), and 
plasmid origins (RSF1010, pBBR1, p15A) (Suppl. Tables 3.1-3.2). We carried out 4 separate in 
vivo studies where EcGT2 donors containing pGT libraries were orally gavaged into conventionally 
raised C57BL6/J mice obtained from commercial vendors. To assess the transfer capacity of 
individual pGT replicative or integrative designs (pBBR1, p15A-Himar, and RSF1010), we 
introduced each pGT library (pGT-L1, pGT-L2, or pGT-L3, respectively) separately into a mice 
cohort from Taconic (Suppl. Figure S3.8). We tested larger combinatorial libraries (pGT-L3 to pGT-
L6) in two independent mice cohorts to assess variability across cohorts (Figure 3.2, Suppl. Figure 
S3.9). To compare in situ transfer in different gut communities, we tested the pGT-L6 library in mice 
from a different source (Charles River) (Suppl. Figure S3.10).  
We performed FACS enrichment and 16S metagenomic analysis on fecal material from all 
mice studies collected over time after oral gavage of pGT libraries (Figure 3.2a). Across in situ 
studies, up to 5% of resulting bacteria appeared to be successful transconjugants (i.e., 
GFP+/mCherry-) six hours post-gavage, compared to control groups (mice gavaged with PBS or 
EcGT2 carrying a non-transferrable vector pGT-NT) (Figure 3.2b, Suppl. Figures S3.8a, S3.9a, 
S3.10a).  These GFP+/mCherry- transconjugants persisted for up to 72 hours post-gavage (Figure 
3.2c, Supp. Fig S3.9b). 16S metagenomic sequencing of these transconjugant populations 
revealed a wide phylogenetic breadth (Figure 3.2d, Suppl. Figures S3.8b, S3.9c, S3.10b). 
Importantly, we observed significant reproducible enrichment of Proteobacteria and Firmicutes, 
especially Clostridiales and Bacillales, amongst successful transconjugants across multiple 
independent experiments. Using the same pGT-L6 library in mice from different vendors, which 
harbored distinct microbiomes (Suppl. Figure S3.10c), yielded shared and distinct 
transconjugants (Suppl. Figure S3.10d). In parallel to FACS-metagenomic studies, we isolated 
individual transconjugants from these fecal samples by selective plating for the payload antibiotic 
resistance gene and confirmed the presence of the GFP-AbR payload by PCR (Figure 3.2e). 
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Across all experiments, we isolated and validated over 297 transconjugants belonging to 19 genera 
across 4 phyla (Suppl. Figure S3.11, Suppl. Table 3.4), validating the capacity of MAGIC to 
broadly transfer genetic material in situ into diverse recipients in the mammalian gut. In contrast, 
only 7 genera could be isolated from in vitro conjugation experiments using the same pGT vectors 
despite comparable diversity of transconjugants detected by FACS-metagenomics (Suppl. Figure 
S3.7). This difference may be due to in vitro conditions that sub-optimally support growth of diverse 
species during conjugation reactions, which underscores the value of implementing MAGIC in situ 
in an established complex microbiome.  
Since transconjugants were no longer detected by 72 hours in situ (Figure 3.2c, Suppl. 
Figure S3.9b), we speculated that the genetic payload (GFP-AbR) on pGT vectors might be 
unstable or toxic, thus causing its negative selection in transconjugants. This hypothesis was tested 
in vitro by 20-30 serial passages of two transconjugant isolates of Escherichia fergusonii that 
contained the GFP-carbR payload either on a pGT-B1 (replicative pBBR1 origin) or a pGT-Ah1 
(integrative Himar transposon) plasmid (Suppl. Figure S3.12). For the pGT-B1 population, we 
observed a significant increase in the fraction of GFP(-) cells (Suppl. Figure S3.12a-c). PCR assay 
of the origin of replication indicated that the pGT-B1 plasmid was no longer present in these GFP(-
) cells (Suppl. Figure S3.12d). In contrast, cells in the pGT-Ah1 population remained GFP(+) 
despite a detectable loss of the plasmid in parts of the population over time (Suppl. Figure S3.12 
e-g), which suggests a more stable maintenance of the GFP-CarbR payload as a integrative 
transposon within the host genome. Together, these results highlight the challenges of maintaining 
long-term in vivo stability of engineered genetic constructs in complex microbial communities, and 
suggest design considerations for more precise tuning of payload life-span and for improving 
payload biocontainment.  
Microbes in the wild are known to possess a variety of natural mobile DNA elements and 
conjugation systems. Whole genome sequencing of three transconjugant strains of Proteus 
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mirabilis and Escherichia fergusonii from our studies (designated as Modifiable Gut Bacteria 
MGB3, MGB4, and MBG9) revealed the presence of putative endogenous DNA mobilization 
systems (Suppl. Figure S3.13a-c). We wondered whether these native mobilization systems could 
interface with our engineered pGT vectors and thus performed in vitro conjugations of the MGB 
strains with laboratory E. coli recipients. Surprisingly, we discovered that MGB4 and MGB9 (both 
E. fergusonii) were able to mobilize pGT vectors into recipients, although at a lower efficiency 
than our engineered EcGT2 donor (Figure 3.3a, Suppl. Figure S3.13d). These results suggest 
that some native gut bacteria can promote secondary transfer of engineered payloads using their 
endogenous conjugation machinery, which may improve payload transfer in situ. 
In general, non-gut adapted bacteria, including common probiotics, do not colonize an 
established gut microbiome. Infiltration of foreign species usually requires drastic perturbations, 
such as use of broad-spectrum antibiotics to suppress the natural flora. Even then, exogenous 
species do not persist upon discontinuation of antibiotic suppression140. Since our donor strains did 
not readily colonize the murine gut and transconjugants were lost soon after (Figure 3.2c, Suppl. 
Figures S3.9b, S3.14a), we reasoned that using a colonizing donor strain may extend the 
persistence of payload constructs in situ. To explore this possibility, we first tested whether a 
mixed population of MGB strains (MGB3, MGB4, MGB9) could stably recolonize the native murine 
gut after a single oral dose without any antibiotic co-administration (Figure 3.3b). In sharp contrast 
to the rapid loss of a non-gut-adapted strain (EcGT1) within 48 hours, MGB strains (especially 
MGB4) recolonized the murine gut and stably persisted for at least 15 days (Figure 3.3c, Suppl. 
Figure S3.15a), populating along the entire gastrointestinal tract (Suppl. Figure S3.15b). FACS 
enrichment and 16S sequencing of GFP-expressing bacteria in feces from these mice revealed 
transconjugants resulting from in situ transfer of the pGT payload from MGB strains to the native 
microbiome after 6 hours (Figure 3.3d) and even 11 days post-gavage  (Suppl. Figure S3.15c). 
These transconjugant populations had similar phylogeny although less diversity than those from 
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prior in situ experiments using the non-colonizing EcGT2 donor (Figure 3.2d, Suppl. Figure 
3.9c). Together these results highlight the utility of MAGIC to isolate host-derived engineerable 
strains that can be modified and then used to stably recolonize the native community and mediate 
further transfer of engineered functions in situ.  
In summary, MAGIC enables metagenomic infiltration of genetic payloads into a native 
microbiome and isolation of genetically modifiable strains from diverse communities. These 
modifiable native strains can then be reintroduced into their original community to maintain 
engineered functions via sustained vertical and horizontal transmission in situ. Future improvements 
to the system, such as optimization of vector stability and donor strain dosage (Suppl. Figure 
S3.14b), could enable better quantitative and temporal control of retention of genetic payloads in 
situ, which may be useful in applications requiring short-term or long-term actuation of engineered 
functions32, 141, 142. Designing genetic programs based on recipient-specific properties should 
enhance targeted execution of desired functions only in a defined subset of species in a 
community143, 144. Beyond the gut microbiome, MAGIC and complementary strategies to engineer 
the horizontal gene pool can facilitate programmable execution of genetic circuits in other microbial 
communities64, 95, 145, 146. Isolation of genetically tractable representatives from diverse microbiomes 
will expand the repertoire of new microbial chasses for emerging applications in synthetic biology 
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Media, chemicals and reagents. E. coli, S. enterica, V. cholera, and P. aeruginosa strains were 
grown in rich LB-Lennox media (BD) buffered to pH 7.45 with NaOH in aerobic conditions at 37°C, 
while L. reuteri was grown in MRS media (BD). B. thetaiotaomicron and E. faecalis were grown 
anaerobically at 37°C in Gifu Anaerobic Modified Medium (GAM) (Nissui Pharmaceutical) or BHI 
media (BD) supplemented with cysteine (1 g/L), hemin (5 mg/L), resazurin (1 mg/L), and Vitamin 
K (1 µL/L). All gut bacteria used in the study were grown in LB-Lennox or Gifu Anaerobic Modified 
Medium (GAM). Antibiotics were used at the following concentrations to select for E. coli: 
chloramphenicol (chlor) at 20 µg/ml, carbenicillin (carb) at 50 µg/ml, spectinomycin (spec) at 250 
µg/ml, kanamycin (kan) at 50 µg/ml, tetracycline (tet) at 25 µg/ml, and erythromycin (erm) at 25 
µg/ml. Antibiotics were used at the following ranges of concentrations to select for transconjugant 
gut bacteria: chloramphenicol (chlor) at 5-20 µg/ml, carbenicillin (carb) at 10-50 µg/ml, tetracycline 
(tet) at 5-25 µg/ml. Diaminopimelic acid (DAP) was supplemented at 50 µM as needed. 
 
Isolation of live murine gut bacteria. Fresh fecal pellets were harvested from mice, and live gut 
bacteria were isolated by mechanical homogenization. Briefly, 250 µL of PBS was added to 
previously weighed pellets in a microcentrifuge tube. Pellets were thoroughly mechanically 
disrupted using a motorized pellet pestle before adding 750 µL of PBS. The disrupted pellets in 
PBS were then subjected to four iterations of vortex mixing for 15 sec at medium speed, 
centrifugation at 1,000 rpm for 30 sec at room temperature, recovery of 750 µL of supernatant 
into a new tube, and replacement of that volume of PBS before the next iteration. The resulting 3 
ml of isolated cells were pelleted by centrifugation at 4,000xg for 5 min at room temperature, the 
supernatant was discarded, and cells were re-suspended in 0.5-1.0 ml of PBS. All gut bacteria 




Donor strain construction. Donor strains EcGT1 and EcGT2 were derived from the S17 λpir E. 
coli strain147 by generating modifications ∆galK::mCherry-specR and ∆asd::mCherry-specR, 
respectively, with λ-red recombineering using the pKD46 system148. Synthetic cassettes 
containing constitutively active mCherry and spectinomycin resistance genes were constructed 
with ~40 bp of homology on both ends to galK or asd flanking regions on the E. coli genome. 100 
ng of mCherry-specR cassette DNA were electroporated into recombineering-competent S17-
pKD46 cells. Cells were allowed to recover in 3 mL LB+carb at 30ºC for 3 hours prior to plating 
on LB+spec. Spectinomycin-resistant colonies were genotyped by PCR for validation of 
mutations. The pKD46 recombineering plasmid was cured out of validated recombinants by 
growth at 37ºC in the absence of carbenicillin to yield the EcGT1 and EcGT2 strains used 
throughout the study. When generating the EcGT2 strain, the growth media was supplemented 
with DAP at all stages of the protocol.  
 
Plasmid construction. pGT vectors were designed to have modular components (e.g., 
selectable markers, regulatory elements, replication origins) that are interchangeable by 
isothermal assembly (ITA) or Golden Gate Assembly. Vector selection markers for E. coli were 
constitutively expressed, while the deliverable cargo or transposase cassettes were expressed 
using different regulatory elements to enable broad-host or narrow-host range gene expression. 
Regulatory elements used in this study exhibit a range of activity (Suppl. Table 3.1). Vector 
libraries used in this study are detailed in Suppl. Table 3.2. Full vector component sequences 
are listed in Suppl. Table 3.3. The non-transferrable vector pGT-NT used as a negative control 




All plasmids were constructed by isothermal assembly (ITA) with NEBuilder HiFi DNA 
Assembly Master Mix (New England Biolabs). Component parts were made by high-fidelity PCR 
with Q5 (NEB) or KAPA Hifi (Kapa Biosystems) polymerases, using existing vectors or gBlocks 
(Integrated DNA Technologies) as PCR templates. PCR products were digested with DpnI (NEB) 
and purified with the QIAquick PCR purification kit (Qiagen) prior to ITA and transformation into 
E. coli. All assembled plasmids were Sanger sequence-verified. 
 
In vitro MAGIC studies on synthetic recipient community. Donor strains harboring pGT 
vectors and representative recipients (E. coli MG1655, S. enterica ATCC 700931, V. cholera 
C9503, P. aeruginosa PA01, E. faecalis ATCC 29200, L. reuteri ATCC 23272, B. thetaiotaomicron 
ATCC 29148) were grown overnight in appropriate media and cultivation conditions, and a 1:1000 
dilution culture was re-grown for 14 hours at 37ºC prior to conjugation studies. To prepare cells 
for in vitro conjugation, donor and recipient populations were washed twice in PBS and cells were 
quantified by OD600 or flow cytometry using SYTO9 staining (Thermo Fisher). 108 donor cells and 
108 recipient cells were mixed together, pelleted by centrifugation, and re-suspended in 10µL 
PBS. Donor and recipient mixes were spotted on an agar plate and incubated for 5 hours at 30ºC 
or 37ºC for conjugation. In vitro conjugations were performed on LB-Lennox (E. coli, S. enterica, 
V. cholera, P. aeruginosa, E. faecalis), MRS (L. reuteri), or supplemented BHI agar (B. 
thetaiotaomicron). Post-conjugation, cells were scraped from the plate into 1 mL PBS, and 100 
uL was plated on appropriate antibiotics and incubated overnight at 30ºC or 37ºC to determine 
the number of colony forming units (CFU) of transconjugants.  
 
In vitro MAGIC studies on natural recipient community. Donor strains harboring pGT vectors 
were streaked onto LB-Lennox agar plates with appropriate antibiotics and supplements, grown 
at 37ºC overnight, and then grown from a single colony in 2 mL liquid media for 10 hours at 37ºC 
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prior to conjugation. The recipient community was isolated anaerobically from fresh murine feces 
as described above, immediately before conjugation. Donor cells were washed twice in PBS and 
quantified by OD600, while recipient cells were quantified by flow cytometry using SYTO9 staining. 
108 donor cells and 109 recipient cells were mixed, pelleted by centrifugation at 5000 x g, and 
resuspended in 25 µL PBS. The mixes were spotted on PBS + 1.5% agar plates and incubated 
at 37ºC either aerobically or anaerobically overnight (9-10 hours). Post-conjugation, cells were 
scraped from the plate into 1 mL of PBS and subjected to antibiotic selection on GAM media, 
FACS enrichment, and metagenomic 16S analysis (see below). 
 
In vitro assessment of pGT vectors horizontal gene transfer mediated by natural isolates. 
MGB natural isolates harboring pGT vectors (MGB3, MGB9, MBG4) were conjugated with a 
recipient E. coli strain harboring a kanamycin resistance plasmid compatible with pGT vectors. 
Prior to conjugations, all strains were streaked onto GAM agar plates with appropriate antibiotics, 
grown at 37ºC overnight, and then grown from a single colony in 5 mL liquid GAM for 10 hours at 
37ºC prior to conjugation. MGB donor and recipient cells were washed twice in PBS and quantified 
by OD600. 109 cells each of MGB and recipient strains were mixed, pelleted by centrifugation at 
5000 x g, and resuspended in 15 µL PBS. The mixtures were spotted on GAM agar plates and 
incubated at 37ºC aerobically for 6 hours. Post-conjugation, cells were scraped from the plate into 
1 mL of PBS and plated on selective and non-selective GAM media. Conjugation efficiency was 
calculated as 𝑡𝑡
𝑛𝑛
, where t is the number of E. coli transconjugant CFUs and n is the total number 
of E. coli CFUs. 
 
Measurement of GFP expression in MGB strains.  MGB isolates harboring pGT vectors 
(MGB3, MGB9, MBG4) were streaked onto GAM agar plates with appropriate antibiotics, grown 
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at 37ºC overnight, and then diluted to OD600 0.001 in liquid GAM into a 96 well plate. The plate 
was incubated in a Synergy H1 (BioTek) microplate reader for 24 hours at 37ºC with orbital 
shaking. Measurements of OD600 and GFP expression (excitation 488 nm, emission 510 nm) were 
taken using Gen5 software (BioTek) at the end of 24 hours. 
 
In vivo MAGIC studies in mice. Conventionally raised C57BL/6 female mice (Taconic 
Biosciences or Charles River Laboratories) were used throughout the study. Two control groups 
of 4 mice each were gavaged with PBS and EcGT2 containing a non-transferable GFP vector 
(pGT-NT). Three to four mice were used in each group gavaged with a pGT donor mix or with 
MGB strains. To equilibrate the murine gut microbiome ahead of time, mice from multiple litters 
were mixed, co-housed for at least 1 week prior to all experiments, and randomly allocated into 
groups. Mice were gavaged with 109 donor cells (EcGT2 or MGB strains) in 300 uL of PBS at 8-
10 weeks old. Control mice were gavaged with 300 uL of PBS. Fecal matter was collected 
immediately before gavage and periodically after gavage to analyze the resulting microbiome 
populations by FACS, metagenomic 16S sequencing, and plating. Upon completion of the study, 
mice were euthanized and small and large intestinal tissues were extracted. Luminal contents 
were washed from each tissue sample with PBS and bacteria were extracted by homogenization 
of the luminal contents for plating and final CFU determination.  
 
Flow cytometry and fluorescence-activated cell sorting (FACS) measurements. Gut bacteria 
isolated from fresh fecal pellets were analyzed for evidence of successful conjugation on a flow 
cytometer (Guava easyCyte HT) using red (642 nm) and blue (488 nm) lasers with Red2 and 
Green photodiodes to detect mCherry (587/610 nm) and sfGFP (485/510 nm) fluorescence, 
respectively. Bacteria at 100x and 1,000x dilutions in PBS were used for optimal detection of 
donor (GFP+/mCh+), gut microbes without a transferred vector (GFP-/mCh-), and transconjugants 
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(GFP+/mCh-). Data were collected and analyzed usingInCyte 3.1 software. For FACS enrichment 
studies, a BD FACS Aria II cell sorter operated with BD FACSDiva software was used to gate for 
sfGFP (FITC filter 515/10nm) and mCherry (mCherry filter 616/26nm). A double gating on GFP 
and mCherry channels was used to select for cells with GFP+/mCh- fluorescence. In addition, 
background events were also taken into account by using the GFP+/mCh- fluorescence detected 
in the fecal sample prior to gavage as baseline signal. An increase over the baseline signifies an 
enrichment of transconjugants. Population density (cells/gram fecal matter) was calculated based 
on number of cells sorted over the mass of the sorted fecal sample. Additional plating and direct 
colony counting were used to validate flow cytometric measurements. FACS plots were formatted 
using FCS Express 6. 
 
Fluorescence microscopy of fecal bacteria. Bacteria were suspended in PBS and centrifuged 
at 5000xg to concentrate into a smaller volume, which varied depending on the concentration of 
bacteria. The bacteria were resuspended by pipetting, and a volume of 15 uL was dropped onto 
a Superfrost Plus microscope slide (Thermo Shandon) and covered with a glass cover slip. Slides 
were air-dried until the PBS receded from the edges of the cover slip and then sealed with clear 
nail polish. Bacteria were imaged at 40x magnification on a Nikon Eclipse Ti2 microscope on 
bright field, RFP, and GFP channels using NIS-Elements-AR software. 
 
Validation of pGT vectors in transconjugants. Transconjugant validation was performed by 
colony PCR of the GFP-antibiotic resistance payload and/or the pGT vector backbone. PCR 
products with the expected size were further verified by Sanger sequencing. Taxonomy 
assignment of isolated colonies was based on 16S rRNA PCR amplification and Sanger 




In vitro evolution of transconjugant gut bacteria. Escherichia fergusonii transconjugants 
MGB4 and MGB9 were serially passaged in LB media for 11-15 days. Starting from a single 
colony, the strains were inoculated into LB and grown at 37C with shaking. Every 12 hours the 
liquid culture was diluted 1:1000 into fresh LB media. At selected time points an aliquot of the 
saturated culture was plated on selective (50 µg/mL carbenicillin) and non-selective plates to 
quantify the percentage of cells expressing the payload antibiotic resistance and GFP genes. 
MGB9 cultures were also plated on selective plates with 20 µg/mL chloramphenicol to check for 
maintenance of the plasmid backbone. 
 
Metagenomic 16S sequencing. Genomic DNA was extracted from isolated bacteria populations 
using the MasterPure Gram Positive DNA Purification Kit (Epicentre). PCR amplification of the 
16S rRNA V4 region and multiplexed barcoding of samples were performed based on previous 
protocols149. The V4 region of the 16S rRNA gene was amplified using customized primers based 
on the method described in Kozich et al.149 with the following modifications: (i) alteration of 16S 
primers to match updated EMP 505f and 806rB primers150-152 and (ii) use of NexteraXT indices 
such that each index pair is separated by a Hamming distance of >2 and Illumina low-plex pooling 
guidelines can be used. Sequencing was performed using the Illumina MiSeq system (500V2 kit).  
 
Analysis of 16S next-generation sequencing (NGS) data. Bacteria from fecal samples taken 
right before gavage (T0) and 6 hours post-gavage (T6) and were sorted by FACS to enrich for 
transconjugants. The compositions of the sorted transconjugant and total populations for each 
sample were determined from 16S sequencing data using the UPARSE pipeline153 (USEARCH 
version 10.0.240) to generate Operational Taxonomic Unit (OTU) tables and abundances and the 
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RDP classifier154 to assign the taxonomy. Phylogenetic associations were analyzed at the genus 
level with at least 90% confidence for 16S assignment. In all MiSeq runs, two blank controls with 
sterile water as input material were included to check for contaminants in the reagents and to filter 
out contaminant OTUs if present. Reads mapping to non-bacterial DNA (e.g., mitochondria, 
plastids, or other eukaryotic DNA) were also excluded from analysis. Only OTUs with more than 
10 reads were considered in downstream analysis.  
Relative abundances of OTUs in unsorted total fecal populations were calculated as the 
normalized number of reads in a sample. Relative abundances of OTUs in T0 FACS-enriched 
populations were used to measure false positive background fluorescence, which was subtracted 
from the T6 transconjugant populations. The corrected relative abundance of each OTU in a T6 
FACS-enriched population is given by the formula:  
𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠 =  
𝑅𝑅6,𝑖𝑖 ∗ 𝑁𝑁6 − 𝑅𝑅0,𝑖𝑖 ∗ 𝑁𝑁0
∑ (𝑅𝑅6,𝑖𝑖 ∗ 𝑁𝑁6 − 𝑅𝑅0,𝑖𝑖 ∗ 𝑁𝑁0)𝑖𝑖
 
where 𝑅𝑅𝑅𝑅𝑡𝑡,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠  is the corrected relative abundance of OTU 𝑖𝑖 at time 𝑡𝑡, 𝑅𝑅𝑡𝑡,𝑖𝑖 is the normalized 
number of reads of OTU 𝑖𝑖 at time 𝑡𝑡 in the FACS-sorted sample, and 𝑁𝑁𝑡𝑡 is the fraction of mCherry-
/GFP+ FACS-sorted events at time 𝑡𝑡. OTUs for which 𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠 is negative are eliminated from 
subsequent analysis, and all remaining 𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠 values are renormalized. 
The fold enrichment of each OTU in the FACS-sorted population is defined as its relative 
abundance in the FACS-sorted population divided by its relative abundance in the unsorted total 
population at T6. To overcome the problem of detection limits (i.e., OTU 𝑖𝑖 appears in the sorted 
population but is below the detection limit in the total population), we added a pseudo-count of 𝑝𝑝 
to all relative abundances when calculating fold enrichments. 𝑝𝑝 is given by 
𝑝𝑝 = 10⌊−log10 𝑛𝑛⌋ 
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where 𝑛𝑛 is the total number of reads in the FACS-sorted sample and ⌊−log10 𝑛𝑛⌋ is the floor function 
- the greatest integer less than or equal to - of −log10 𝑛𝑛. The fold enrichment of OTU 𝑖𝑖 with the 
pseudo-count correction is calculated as 
𝐹𝐹𝑖𝑖 =
𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠  +  𝑝𝑝
𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑢𝑢𝑛𝑛𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠  +  𝑝𝑝
 
If the relative abundance of OTU 𝑖𝑖 in the unsorted population is below the detection limit, then 
the fold enrichment is calculable as  𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 + 𝑝𝑝
𝑝𝑝
 , instead of  𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
0
.  
The pseudo-count-corrected fold enrichment 𝐹𝐹𝑖𝑖 overestimates the true fold enrichment 
( 𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑢𝑢𝑢𝑢𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠








𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠  +  𝑝𝑝
𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑢𝑢𝑛𝑛𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠  +  𝑝𝑝
 ≤  
𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠  +  𝑝𝑝
𝑅𝑅𝑅𝑅6,𝑖𝑖,𝑢𝑢𝑛𝑛𝑠𝑠𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠




In all heat maps showing fold enrichment versus relative abundance, only OTUs with 𝐹𝐹𝑖𝑖 > 10 
are displayed to show more stringent and high confidence results. R code for this analysis is 
available upon request. 
 
Whole genome sequencing of engineered mouse gut bacteria (MGB) isolates. To sequence 
MGB isolates, we prepared a sequencing library using the Nextera kit (Illumina) and utilized the 
Illumina HiSeq 2500 platform for 100 bp single-end reads. The SPAdes single cell assembler 
pipeline (version 3.9.1)155 was employed to generate whole genome contigs. BLAST and 
PlasmidFinder (version 1.3)156 were used to analyze the sequences and identify native 
mobilization systems. Geneious (version 7.1.5) was used to visualize contig alignments to 





Figure 3.1. Overview of Metagenomic Alteration of Gut microbiome by In situ Conjugation 
(MAGIC). (a) In contrast to traditional approaches to cultivate microbes first and then test for 
genetic accessibility, MAGIC harnesses horizontal gene transfer in the native environment to 
genetically modify bacteria in situ. Transconjugant bacteria can be detected by FACS or antibiotic 
selection and further manipulated. (b) MAGIC implementation to transfer replicative or integrative 
pGT vectors from an engineered donor strain into amenable recipients in a complex microbiome. 
Replicative vectors feature a broad-host range origin of replication (oriR), while integrative vectors 
contain a transposable Himar cassette and transposase. The donor E. coli strain contains 
genomically integrated conjugative transfer genes (tra) and a mCherry gene. Transconjugant 
bacteria are detectable based on expression of an engineered payload that includes GFP and an 






Figure 3.2. Identification and isolation of genetically tractable bacteria from the murine gut 
using MAGIC. (a) Implementation of MAGIC in a murine model with fecal bacterial analysis by 
FACS, antibiotic selection, and sequencing. (b) FACS dot plots of fecal bacteria, pre- and post-
gavage of EcGT2 donors containing pGT-L3 or pGT-L6 vector libraries. Green boxes define the 
sorted GFP+/mCherry- transconjugant populations. For each vector library, fecal samples from 3 
co-housed mice were independently evaluated by flow cytometry with similar results. (c) 
Longitudinal analysis of fecal microbiome by flow cytometry for presence of EcGT2 pGT-NT donor 
cells (red triangles, n= 4 mice) and transconjugants of vector libraries pGT-L3 (purple circles, n=3 
mice), pGT-L6 (maroon circles, n=3 mice), pGT-NT control (green circles, n= 4 mice), or PBS (no 
donor) control (orange circles, n=2 mice). Donor cells and transconjugants were lost within 48 
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hours. The dotted line shows the detection limit. (d) 16S taxonomic classification of 
transconjugants (GFP+/mCh-) enriched by FACS of pGT-L3 and pGT-L6 recipient groups. Each 
column represents transconjugants from one mouse. Each OTU's relative abundance in the total 
bacterial population is shown in the grayscale heat-map, while each OTU's fold enrichment among 
transconjugants is shown in the orange heat-map.. Bracketed values indicate confidence of 
taxonomic assignment by RDP classifier. Genera with successfully cultivated isolates are denoted 
by white stars. (e) PCR confirmed the presence of the antibiotic resistance/GFP payload cassette 
from pGT-L3 and pGT-L6 vectors in diverse isolates that were engineered in the murine gut and 
isolated by selective plating with carbenicillin or tetracycline. NA indicates 16S sequences that were 








Figure 3.3. Transconjugant native gut bacteria recolonize the gut and mediate secondary 
transfer of engineered genetic payloads. (a) Left panel: GFP expression profiles of three 
isolates (MGB3, MGB4, MGB9; n=5 for each) versus control strain (E. coli MG1655, n=5). MGB 
isolates were P. mirabilis (orange bar) and E. fergusonii (blue bars) containing either vector pGT-
Ah1 (red border) or vector pGT-B1 (purple border). E. fergusonii strains were genetically identical, 
but received two different vectors. Right panel: efficiency of in vitro conjugation of pGT vectors 
from MGB strains to E. coli MG1655 recipients. EcGT2 donors were used as positive controls 
(gray bars). Sample sizes are n=2-4. Bars indicate means; error bars indicate standard deviation. 
(b) Schematic diagram of experiment: genetically tractable gut microbiota were isolated from the 
murine microbiome in vitro and then orally gavaged to recolonize the gut. (c) Colonization of MGB 
strains and EcGT2 lab strain in mice (n=6, n=4 respectively) over time, after initial oral gavage. 
Cell densities were determined by both plating (light green) and flow cytometry (dark green) of 
fecal bacteria, and by flow cytometry for E. coli (orange). Error bars indicate standard deviation. 
(d) FACS enrichment and 16S taxonomic classification of top in vivo transconjugants at 6 hours 
post-gavage with MGB strains. Fecal samples from 6 mice were combined for analysis. Each 
OTU's relative abundance in the total bacterial population is shown in the grayscale heat-map, 
while each OTU's fold enrichment among transconjugants is shown in the orange heat-map. 
Bracketed values indicate confidence of taxonomic assignment by RDP classifier. Red asterisks 






Supplementary Figure S3.1. Plasmid maps of vectors used in this study. (a) Map of Himar 
transposon integrative vectors (pGT-Ah and pGT-Kh variants found in libraries L2, L4, L5, L6, L7 
and L8). (b) Map of replicative vectors with pBBR1 origin of replication (pGT-B variants found in 
libraries L1, L4, and L6). (c) Map of replicative vectors with RSF1010 origin of replication (pGT-S 
variants found in library L3). Although this vector backbone contain genes involved in conjugation 






Supplementary Figure S3.2. FACS gating methodology for isolation of transconjugant 
bacteria. (a) Illustration of FACS enrichment method to isolate transconjugant cells from complex 
recipient populations. GFP and mCherry fluorescence are used to gate cell populations consisting 
of E. coli donors and diverse recipients. Quadrants Q1 and Q2 correspond to donor cells (mCh+), 
while un-manipulated recipients are in quadrant Q3. Quadrant Q4 contains transconjugants that 
received the GFP gene cargo and are not naturally mCherry fluorescent (GFP+, mCh-). Q4 cells 
are isolated and further analyzed. This gating was used to analyze fecal samples from each 
individual mouse in each in situ experiment, as well as every in vitro conjugation in this study by flow 
cytometry. (b) To validate the FACS enrichment method, GFP+ E. coli were mixed with a natural 
murine fecal bacterial community at given levels (1-100% of population) and retrieved by FACS. 
16S sequencing of the samples showed that the fluorescent E. coli were efficiently and specifically 
enriched by FACS. Although the raw Q4 population contained some autofluorescent cells, the 







Supplementary Figure S3.3. pGT vectors were transferred from E. coli donors to 
representative recipient species during in vitro conjugations. (a) In vitro conjugation 
efficiency of replicative vector pGT-B1 from E. coli donor to various recipients, which are plotted 
by phylogenetic relationships. (b) In vitro conjugation efficiency of vector pG-Ah1 between E. coli 
donor and various recipients. This vector is replicative only in Proteobacteria (E. coli, S. enterica, 
V. cholera, P. aeruginosa) but delivered genetic cargo by transposition into a broader array of 
bacteria. Asterisks indicate cultures grown in anaerobic conditions, while all other cultures were 






Supplementary Figure S3.4. pGT vectors were transferred from E. coli donors to murine 
fecal bacteria during in vitro conjugations. (a) In vitro conjugation of pGT vectors from EcGT2 
donor strain into fecal bacteria extracted from murine feces. (b) Aerobic (top) and anaerobic 
(bottom) conjugations were performed using EcGT2 strains containing no vector (mock 
conjugation), a nontransferable vector (pGT-NT), pGT-L3, pGT-L7, and pGT-L8. Aerobic 
conjugations were plated on selective and non-selective media and grown aerobically at 37C for 
24 hours. Anaerobic conjugations were plated on selective and non-selective media, grown 
anaerobically at 37C for 48 hours, and exposed to oxygen at room temperature for 48 hours. Red 
arrows indicate GFP+ CFUs on nonselective plates. (c) Efficiencies of aerobic (top) and anaerobic 
(bottom) conjugations. Aerobic conjugation efficiencies were calculated from 3 independent 






Supplementary Figure S3.5. FACS enriches for GFP+, antibiotic-resistant transconjugant 
gut bacteria arising from in vitro conjugations. (a) Implementation of FACS enrichment of in 
vitro conjugations. (b) Conjugations between EcGT2 harboring vector libraries pGT-L3, pGT-L7, 
and pGT-L8 and murine fecal bacteria were performed aerobically overnight. A mock conjugation 
using EcGT2 with no vector and a negative control conjugation using the pGT-NT non-
transferable vector were also performed. 20,000 FACS sorted events from Q3 (mCherry-/GFP-) 
and Q4 (mCherry-/GFP+) populations were plated on selective and non-selective media and 
grown aerobically to select for transconjugants. Cultivable aerobic transconjugants of pGT-L3 and 
pGT-L7 vectors were successfully enriched by FACS, although GFP+ CFUs may appear dim 







Supplementary Figure S3.6. FACS enriches for GFP+, antibiotic-resistant transconjugant 
gut bacteria arising from in vitro conjugations. (a) Implementation of FACS enrichment of in 
vitro conjugations. (b) Conjugations between EcGT2 harboring vector libraries pGT-L3, pGT-L7, 
and pGT-L8 and murine fecal bacteria were performed aerobically overnight. A mock conjugation 
using EcGT2 with no vector and a negative control conjugation using the pGT-NT non-
transferable vector were also performed. 20,000 FACS sorted events from Q3 (mCherry-/GFP-) 
and Q4 (mCherry-/GFP+) populations were plated on selective and non-selective media and 
grown aerobically to select for transconjugants. Cultivable aerobic transconjugants of pGT-L3 and 
pGT-L7 vectors were successfully enriched by FACS, although GFP+ CFUs may appear dim 







Supplementary Figure S3.7. Identification of FACS-enriched in vitro transconjugants by 
16S sequencing. (a) FACS dot plots of in vitro conjugations of murine gut bacteria and EcGT2 
donors with vector libraries pGT-L1, L3, and L7. This experiment was performed 3 times with 
similar results. Green boxes define the sorted GFP+/mCherry- transconjugant populations. (b) 16S 
taxonomic classification of in vitro GFP+/mCherry- transconjugants of pGT-L1, L3, and L7 enriched 
by FACS. Relative abundance of each OTU in the unsorted population is shown in the grayscale 
heat-map, while fold enrichment for transconjugants of each OTU is shown in the orange heat-
map with annotated taxonomic identities. Bracketed values indicate confidence of taxonomic 
assignment by RDP classifier. Genera with successfully cultivated isolates are denoted by stars. 
Each column represents FACS-enriched transconjugants from one conjugation. (c) Comparison 
of OTUs shared between transconjugants arising from each vector library during in vitro 
conjugations. 18 OTUs were shared between all 3 libraries, with a total of 47 OTUs being shared 






Supplementary Figure S3.8. Identification of FACS-enriched in situ transconjugants by 16S 
sequencing. (a) FACS dot plots of in situ conjugations using EcGT2 donors with vector libraries 
pGT-L1, L2, and L3. Green boxes define the sorted GFP+/mCherry- transconjugant populations. 
Each plot shows fluorescence expression of bacteria from the combined fecal samples of 3 co-
housed mice. The experiment was run 3 independent times with similar results. (b) 16S taxonomic 
classification of FACS-enriched transconjugants from in situ mouse experiments using vector 
libraries pGT-L1, L2, and L3. Relative abundance of each OTU in the unsorted population is 
shown in the grayscale heat-map, while fold enrichment for transconjugants of each OTU is 
shown in the orange heat-map with annotated taxonomic identities. Bracketed values indicate 
confidence of taxonomic assignment by RDP classifier. Each column represents data from a 
91 
 
separately housed cohort of 3 mice whose fecal samples were combined for analysis. Genera 
with successfully cultivated isolates are denoted by stars. (c) The pGT-L3 transconjugant 
population from (b) was further analyzed by comparing Q4 enriched OTUs against Q3 OTUs, 
which represent a sample of the GFP- native bacteria population, and by performing enrichment 
analysis of Q4 samples that were sorted again for Q4. Enriched GFP+ transconjugants were 
robust whether compared against the total fecal population or against Q3. 7 out of 11 OTUs 
enriched in Q4 were present in the double-sorted Q4 population, indicating that Q4 sorting is 
robust. The OTUs lost upon double-sorting were obligate anaerobes and likely sensitive to 






Supplementary Figure S3.9. Identification of FACS-enriched in situ transconjugants of 
multi-vector libraries. (a) Flow cytometric quantification of in situ transconjugants in the total 
bacterial population, post-gavage of EcGT2 donors containing pGT-L4 (green, n=4 mice) or pGT-
L5 (blue, n=4 mice) vector libraries. Control groups gavaged with PBS (black, n=2 mice) or donors 
containing a non-transferrable pGT-NT vector (red, n=2 mice) produced no detectable 
transconjugants. Black bars indicate means. (b) Longitudinal analysis of murine fecal microbiome 
by flow cytometry for presence of transconjugants post-gavage of EcGT2 donors containing pGT-
L4 (green, n=6 mice), or pGT-L5 (blue, n=6 mice). Donor cells of these libraries (orange, n=12 
mice) were lost within 48 hours, while transconjugants were observed up to 72 hours post-gavage. 
The dotted line indicates the detection limit of flow cytometry. Error bars indicate standard 
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deviation. (c) 16S taxonomic classification of transconjugants (GFP+/mCh-) enriched by FACS of 
pGT-L4 and pGT-L5 recipient groups. Relative abundance of each OTU in the unsorted 
population is shown in the grayscale heat-map on the left, while fold enrichment for 
transconjugants of each OTU is shown in the orange heat-map on the right with annotated 
taxonomic identities. Bracketed values indicate confidence of taxonomic assignment by RDP 
classifier. Each column represents data from 6 mice from 2 independent cohorts whose fecal 







Supplementary Figure S3.10. Identification of FACS-enriched in situ transconjugants in 
mice from a different commercial vendor. (a) FACS dot plots of in situ conjugations using 
EcGT2 pGT-L3 donors in a cohort of mice from a different vendor (Charles River Laboratories). 
Green boxes define the sorted GFP+/mCherry- transconjugant populations. Flow cytometry was 
performed 3 times, on fecal samples from individual co-housed mice, with similar results. (b) 16S 
taxonomic classification of FACS-enriched GFP+/mCherry- transconjugants of pGT-L3. Relative 
abundance of each OTU in the unsorted population is shown in the grayscale heat-map, while 
fold enrichment for transconjugants of each OTU is shown in the orange heat-map with annotated 
taxonomic identities. Bracketed values indicate confidence of taxonomic assignment by RDP 
95 
 
classifier. Each column represents bacteria from one mouse. Genera with successfully cultivated 
isolates are denoted by stars. (c) Metagenomic 16S rRNA sequencing of mouse fecal samples 
shows that mice from different vendors have divergent gut microbiomes, with some shared OTUs. 
(d) In in situ experiments using the same vector library (pGT-L6) in cohorts of 3 mice each from 






Supplementary Figure S3.11. PCR-validated transconjugant isolates from in situ mouse 
experiments. 297 PCR-validated isolates from in situ experiments using vector libraries pGT-L3 
and pGT-L6 were identified by 16S Sanger sequencing and assigned to a genus using RDP 






Supplementary Figure S3.12. Comparison of vector and payload stability in two 
transconjugant isolates. (a) Vector map of pGT-B1. GFP and beta-lactamase genes are 
expressed from separate promoters on a replicative pBBR1 origin plasmid. (b) MGB4, an 
Escherichia fergusonii isolate containing pGT-B1, lost GFP expression over time when serially 
passaged without selection for 15 days. Plating was performed for 3 independent serial passages. 
(c) Quantification of carb-resistant and GFP+ CFUs of MGB4 over time; all CFUs remained carb-
resistant as the population lost GFP expression. Center values are the means of 3 serial 
passages; error bars represent standard deviation. (d) Colony PCR for the pGT-B1 backbone 
showed that the plasmid was absent in GFP- CFUs at all time points surveyed. Each lane shows 
the PCR product for one colony. This PCR was performed once. (e) Vector map of pGT-Ah1, 
which contains GFP and beta-lactamase genes on a transposable cassette. The plasmid 
backbone contains a chloramphenicol resistance gene for selection. (f) MGB9, an Escherichia 
fergusonii isolate containing pGT-Ah1, remained 100% GFP+ during serial passaging without 
selection over 11 days. Plating was performed for 3 independent serial passages. (g) Over time 
the proportion of MGB9 CFUs expressing the genes on the transposable cassette (GFP+ and 
carb-resistant) remained at 100%, while the chloramphenicol resistance conferred by the pGT-
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Ah1 backbone was lost in some of the population. Center values are the means of 3 serial 






Supplementary Figure S3.13. Characterization of 3 Modifiable Gut Bacteria (MGB) strains 
by whole-genome sequencing and in vitro conjugation. (a) Three distinct MGB strains, 
isolated from in vitro conjugations between E. coli pGT donors and murine fecal bacteria, were 
analyzed by whole-genome sequencing. MGB4 and MGB9 appear to be the same strain isolated 
from separate experiments with different pGT vectors transferred. Sequencing of (b) MGB4/9 and 
(c) MGB3 revealed the presence of genes involved in conjugation and genetic transfer. However, 
only MGB4/9 strains that shared homology with the pECO-fce plasmid were observed to transfer 
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their pGT vectors to E. coli during in vitro conjugations. (d) PCR confirmation of pGT vector 
transfer from MGB4 to an E. coli recipient following in vitro conjugation. The conjugation was 







Supplementary Figure S3.14. Longevity of donor E. coli strains in the murine gut following 
oral gavage. (a) In vivo gut colonization profiles of MAGIC donors EcGT1 (S17, galK::mCherry), 
EcGT2 (S17, asd::mCherry), and control E. coli MG1655 in C57BL/6 mice measured by flow 
cytometry of fecal bacteria after a single gavage of 109 cells. Mean values were calculated using 
feces from 2 gavaged mice; error bars indicate standard deviation. (b) Two orally gavaged doses 
of 109 EcGT1 cells resulted in a longer persistence of this donor in the gut. Mean values were 






Supplementary Figure S3.15. Characterization of MGB recolonization of the murine gut. (a) 
MGB3, MGB4, and MGB9 strains orally gavaged into mice (n=4) as a mixture recolonized the GI 
tract without any antibiotic treatment. MGBs were detectable in fecal samples for at least 15 days 
post-gavage. (b) MGB strains (namely MGB4) were present in all sampled locations along the GI 
tract when the mice (n=4) were euthanized 15 days post-gavage. Error bars represent standard 
deviation. (c) Phylogenetic tree of FACS-sorted GFP+/mCherry-.transconjugants in fecal samples 
from mice after 11 days post-gavage of MGB strains. Fecal samples from 4 mice were combined 
for analysis. Relative abundance of each OTU in the unsorted population is shown in the 
grayscale heat-map, while fold enrichment for transconjugants of each OTU is shown in the 
orange heat-map. Bracketed values indicate confidence of taxonomic assignment by RDP 




Supplementary Table 3.1. List of vectors and vector components. 
Origins of replication (oriR): 
Origin  Copy # Host range Code 
R6K 10-20 Narrow (Proteobacteria) K 
p15A 14-16 Narrow (Enterobacteria) A 
oriV 4-7 Broad (Gram- and Gram+) V 
pBBR1 15-40 Broad (preferably Gram-) B 
RSF1010 12 Broad (Gram- and Gram+) S 
RCR 250-350 Broad (Eubacteria) W 
 
Integrative elements: 
Transposase Transposon inverted repeat Host range Code 
none - - - 
Himar ACAGGTTGGATGATAAGTCCCCGGTCT Broad h 
Tn5 CTGTCTCTTATACACATCT Broad t 
 
Vector selection genes: 
Resistance gene  Antibiotic selection [Ab] in E. coli 
Beta-lactamase Carbenicillin 50 μg/ml 
Chlor Chloramphenicol 20 μg/ml 
Tet Tet 25 μg/ml 
Spec Spec 200 μg/ml 
Kan Kan 50 μg/ml 
 
Cargo selection cassettes: 
Resistance cassette Antibiotic selection [Ab] in E. coli 
GFP-Beta-lactamase Carb 50 μg/ml 
GFP-CatP Chlor 20 μg/ml 
GFP-Tet Tet 25 μg/ml 
GFP-Spec Spec 250 μg/ml 
GFP-Kan Kan 50 μg/ml 






































































pGT-Ah1 GFP-Beta-lactamase 4 Chlor 4 
pGT-Ah2 GFP-Beta-lactamase 5 Chlor 5 
pGT-Ah3 GFP-Beta-lactamase 6 Chlor 6 
pGT-Ah4 GFP-Beta-lactamase 7 Chlor 7 
pGT-Ah5 GFP-CatP 8 Kan 4 
pGT-Ah6 GFP-CatP 8 Kan 5 
pGT-Ah7 GFP-CatP 8 Kan 6 
pGT-Ah8 GFP-CatP 8 Kan 7 
pGT-Ah9 GFP-Tet 4 Chlor 4 
pGT-Ah10 GFP-Tet 4 Chlor 5 
pGT-Ah11 GFP-Tet 4 Chlor 6 
pGT-B1 GFP 1 Beta-lactamase - 
pGT-B2 GFP 2 Beta-lactamase - 
pGT-B3 GFP 3 Beta-lactamase - 
pGT-S1 GFP-Beta-lactamase 4 Beta-lactamase - 
pGT-S2 GFP-Beta-lactamase 5 Beta-lactamase - 
pGT-S3 GFP-Tet 4 Tet - 
pGT-S4 GFP-Tet 5 Tet - 
pGT-Kh1 GFP-Beta-lactamase 4 Chlor 4 
pGT-Kh2 GFP-Beta-lactamase 5 Chlor 5 




Supplementary Table 3.2. Vector libraries used in this study. 
Library Vectors 
pGT-L1 B1, B2, B3 
pGT-L2 Ah5, Ah6, Ah7, Ah8 
pGT-L3 S1, S2, S3, S4 
pGT-L4 Ah1, Ah3, B1, B2, B3 
pGT-L5 Ah5, Ah6, Ah7, Ah8, Ah9, Ah10, Ah11 
pGT-L6 Ah1, Ah3, Ah5, Ah6, Ah7, Ah8, Ah9, Ah10, Ah11, B1, B2, B3 
pGT-L7 Ah1, Ah2, Ah3, Ah4 
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Primers for PCR validation of transconjugants: 
16S forward AGAGTTTGATCATGGCTCAG 
16S reverse CGGTTACCTTGTTACGACTT 
GFP validation primer forward ATGCGTAAAGGCGAAGAGC 
GFP validation primer reverse TTATTTGTACAGTTCATCCATACCATG 
Beta-lactamase validation primer forward ATGAGTATTCAACATTTCCGTGTC 
Beta-lactamase validation primer reverse TTACCAATGCTTAATCAGTGAGGC 
pGT-B backbone validation primer forward CTGCGCAACCCAAGTGCTAC 
pGT-B backbone validation primer reverse CAGTCCAGAGAAATCGGCATTCA 
pGT-Ah backbone validation primer forward ATGGAAAAAAAGGAATTTCGTGTTTTG 
pGT-Ah backbone validation primer reverse TTATTCAACATAGTTCCCTTCAAGAGC 
CarbR internal forward primer CCGAAGAACGTTTTCCAATGATGAG 
GFP internal reverse primer TGATTGTCTGGCAGCAGAAC 
catP (chlor resistance) validation primer forward GCAAGTGTTCAAGAAGTTATTAAGTC 
catP (chlor resistance) validation primer reverse TTAACTATTTATCAATTCCTGCAATTCG 




Supplementary Table 3.4. List of isolated transconjugant strains. Strains are grouped by the 
mouse cohort they were isolated from and the vector library used in the study. All family-level 
assignments were made using the RDP classifier with confidence >0.89. 
Taconic mice in situ conjugations 
Vector 













1 pGT-Ah carb 
Bacteroidaceae Bacteroides 1 pGT-Ah carb 
Enterobacteriaceae  Proteus 1 pGT-Ah carb 
Enterobacteriaceae  Citrobacter 1 pGT-Ah carb 
Enterococcaceae Enterococcus 1 pGT-Ah carb 
Lachnospiraceae Hungatella 0.72 pGT-Ah carb 
Lachnospiraceae Clostridium XlVa 1 pGT-Ah carb 
Lachnospiraceae Anaerostipes 1 pGT-Ah carb 
Lachnospiraceae Moryella 0.19 pGT-Ah carb 
Lachnospiraceae Blautia 1 pGT-Ah carb 
Lactobacillaceae Lactobacillus 1 pGT-Ah carb 
Peptostreptococcaceae Clostridium XI 1 pGT-Ah carb 
pGT-L3 
Coriobacteriaceae Eggerthella 1 pGT-S tet 
Enterobacteriaceae Cosenzaea 0.73 pGT-S tet 
Enterobacteriaceae Proteus 1 pGT-S tet 
Enterococcaceae Enterococcus 1 pGT-S carb 
Lachnospiraceae Lactonifactor 0.7 pGT-S tet 
Lachnospiraceae Clostridium XIVa 1 pGT-S carb 
Lachnospiraceae Hungatella 0.71 pGT-S tet 
Lachnospiraceae Clostridium XIVa 1 pGT-S tet 
Lachnospiraceae Blautia 1 pGT-S tet 
Lachnospiraceae Robinsoniella 0.42 pGT-S tet 
Lachnospiraceae Eisenbergiella 0.99 pGT-S tet 
Lactobacillaceae Lactobacillus 0.89 pGT-S tet 
 
Charles River mice in situ conjugations 
Vector 









Bacteroidaceae  Bacteroides 1 pGT-Ah carb 
Enterococcaceae Enterococcus 1 pGT-Ah carb 
Lactobacillaceae Lactobacillus 1 pGT-Ah carb 





In vitro conjugations 
Vector 









Enterobacteriaceae  Proteus 1 pGT-Ah carb 
Enterococcaceae Enterococcus 1 pGT-Ah carb 
Enterobacteriaceae  Escherichia 1 pGT-Ah carb 
Lactobacillaceae Lactobacillus 1 pGT-Ah carb 
Bacillaceae  Bacillus 1 pGT-Ah carb 
pGT-L3 
Enterobacteriaceae  Escherichia 1 pGT-S carb 
Enterococcaceae Enterococcus 1 pGT-S carb 
Enterobacteriaceae Proteus 1 pGT-S carb 
pGT-L5 
Enterobacteriaceae  Cosenzae 0.89 pGT-Ah chl 
Enterobacteriaceae Proteus 1 pGT-Ah chl 
Burkholderiaceae Cupriavidus 1 pGT-Ah chl 
pGT-L4 
Enterobacteriaceae  Escherichia 1 pGT-Ah carb 
Enterobacteriaceae Proteus 1 pGT-Ah carb 





Chapter 4: Genetic engineering of Segmented Filamentous Bacteria using MAGIC 
 
4.1. Introduction 
 Mammalian gut bacteria are adapted to live in a highly complex environment teeming with 
diverse microbes and a wide range of chemicals arising from food digestion, host metabolism, 
and microbial metabolism. Within this environment, some bacteria occupy niches which are 
difficult or impossible to recapitulate in vitro, making these bacteria recalcitrant to cultivation. 
Although advances in “culturomics” have enabled cultivation of increasing numbers of gut 
commensals, over 20% of known human gut microbes remain uncultivable and difficult to study 
genetically81. The Metagenomic Alteration of Gut microbiome by In situ Conjugation (MAGIC) 
system described in Chapter 3 circumvents the need for cultivation, potentially enabling genetic 
manipulation of undomesticated gut bacteria in situ and greatly expanding the scope of functional 
genetic studies of host-microbiome interactions that can be done. 
One gut bacterium of great interest in the context of host-microbial interactions that 
remains difficult to cultivate is Segmented Filamentous Bacteria (SFB), also known as Candidatus 
Arthromitus or Candidatus Savagella. SFB is a spore-forming, Gram positive member of the 
Clostridiaceae family. The first study of SFB’s habitat, morphology, and life cycle was published 
in 1974, describing segmented, filamentous-shaped bacteria found in the ilea of weaned mice 
and rats that grew with one filament end tightly attached to gut epithelial cells159. Bacteria with 
this morphology were subsequently identified in a wide range of animals, including amphibians, 
fish, birds, and mammals, including monkeys and humans160, 161. In nearly all species examined, 
SFB-like bacteria colonize the ileum and attach directly to the epithelium, suggesting that these 
bacteria occupy similar niches and interact closely with their hosts162. 
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The SFB of mice and rats are the most closely studied out of this panoply of 
morphologically similar bacteria. Early studies in the 1970s used electron microscopy to visualize 
SFB and characterize its life cycle, which involves attachment of a cell to the gut epithelium by a 
holdfast, growth of the filament by division of segments, and differentiation and release of new 
holdfasts from the distal end of the filament163. The use of gnotobiotic mice and rats mono-
associated with SFB has enabled in vivo cultivation of SFB monocultures164, which have been 
used to sequence the SFB genome165, 166. Sequencing studies have shown that SFB is an obligate 
anaerobe with a small genome size (1.6 Mbp) and low genomic GC content (28%) and lacks 
genes for the biosynthesis of most amino acids, vitamins/cofactors and nucleotides167, 168. These 
findings suggest that SFB is an obligate or facultative mammalian symbiont and relies on the host 
for many essential nutrients.  
Mouse studies have shown that SFB directly affects host physiology and disease 
pathogenesis. Colonization with SFB is sufficient to induce differentiation of Th17 cells in the 
small-intestinal lamina propria of germ-free mice and protect the mice against infection by 
Citrobacter rodentium, an intestinal pathogen21. In conventional mice that harbor SFB along with 
other intestinal bacteria, SFB antigens stimulate of over 60% of intestinal Th17 cells, indicating 
that SFB is a dominant microbial signal for Th17 induction96. Furthermore, Th17 induction requires 
SFB colonization and adhesion to the intestine and cannot be caused by presence of SFB 
antigens alone, indicating that that SFB has organismal properties that modulate the host immune 
system96, 169. SFB is host-specific: although rats and mice both have phylogenetically similar SFB, 
each species’ SFB only adheres and induces an immune response specifically in its native host169. 
SFB also induces intestinal IgA secretion and activates intraepithelial lymphocytes170. As a 
consequence of its role as an immune system regulator, SFB modulates the incidence and 
progression of several autoimmune diseases in mouse models. SFB causes experimental 
autoimmune encephalomyelitis171, a model for multiple sclerosis, as well as autoimmune 
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arthritis172, two diseases dependent on Th17 cell activation. Interestingly, SFB protects against 
the development of type 1 diabetes in female, but not male, mice173.  
Given the key role SFB plays in immune regulation and its relevance to autoimmune 
diseases, the biology of SFB warrants further study. The difficulty of cultivating and propagating 
SFB in vitro174, 175 has hindered the development of genetic tools for SFB; SFB has yet to be 
transformed or otherwise genetically manipulated. Because SFB’s unique relationship to the host 
is dependent on the organism itself, functional genetic studies would be invaluable for elucidating 
SFB’s life cycle and symbiosis with the host. In the work described in this chapter, we tested the 
hypothesis that SFB could be genetically manipulated for the first time using the MAGIC system. 
Specifically, we wanted to demonstrate that that SFB could receive engineered DNA by horizontal 
gene transfer from an E. coli donor within the murine gut, and that SFB is capable of expressing 
heterologous genes. The work presented in this chapter describes the design principles for 
optimizing in situ gene transfer and gene expression in an organism with no prior available genetic 
tools, and the experimental principles for measuring trans-gene expression in an uncultivable gut 
commensal. These preliminary studies lay the foundation for future optimization of genetic tools 




Identification of SFB genetic parts and design of MAGIC vectors.  
We aimed to implement MAGIC technology in SFB by in situ conjugative delivery of two 
novel genetically encoded traits, GFP and an antibiotic resistance gene. These two genetic 
functions would enable assessment of trans-gene expression by two orthogonal methods—
measurement of GFP fluorescence by microscopy or FACS, and antibiotic selection (Figure 
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4.1a). The genetic payload was delivered on a conjugative Himar transposon, with an associated 
hyperactive Himar transposase (Figure 4.1b). Because no known replicative plasmids were 
available for SFB, the host-independent, broadly active Himar transposon was used as an 
integrative vector to enable long-term, stable maintenance of the delivered payload in SFB. An 
additional advantage of using an integrative Himar transposon to deliver the payload is that the 
resulting transposon mutant library could potentially be analyzed by transposon sequencing to 
determine genes in SFB that affect fitness (Figure 4.1a).  
Because no toolbox of genetic parts was readily available for SFB, we curated a library of 
antibiotic resistance genes, promoters, and ribosomal binding sites (RBS) that were likely active 
in SFB in order to build the MAGIC vectors. We chose specific antibiotic resistance genes for SFB 
MAGIC vectors based on available Clostridia-specific resistance markers and on experimental 
measurement of SFB’s antibiotic susceptibilities in the mouse gut. To maximize the likelihood of 
conferring a new antibiotic resistance to SFB, we searched the literature for resistance genes 
originally identified in closely related Clostridia, which were more likely to have biological activity 
in SFB. Resistance genes for chloramphenicol (catP) and erythromycin (ermBP) had been 
identified in Clostridium perfringens and were subsequently shown to confer resistance to E. coli 
when cloned into plasmids176-178, suggesting that these genes were broadly active across bacteria 
and likely to also function in SFB. We confirmed that SFB is susceptible to these two drugs by 
treating C57BL/6 mice with antibiotics in drinking water and measuring fecal SFB levels relative 
to all bacteria over time by qPCR (Figure 4.1c). During treatment with either chloramphenicol or 
erythromycin for 4 days, SFB levels dropped significantly and stayed low after antibiotic treatment 
ended. SFB prevalence was not affected by neomycin administration. These results indicate that 
SFB is susceptible to chloramphenicol and erythromycin, but not neomycin, at dosages commonly 




We also sought to optimize expression of the selectable payload and the Himar 
transposase by identifying regulatory elements (promoters and ribosomal binding sites) likely to 
be active in SFB. The native C. perfringens promoter/RBS sequence from plasmid pJIR750178 
was used to drive expression of the payload, a two-gene operon consisting of C. perfringens 
chloramphenicol resistance gene catP and a superfolding GFP gene (sfGFP).  To drive 
expression of the Himar transposase, we used four promoter sequences from the SFB genome 
that were likely to be constitutively active. These promoters were all 110 bp 5’ untranslated regions 
(UTRs) of putative constitutively expressed housekeeping genes in SFB. We identified these 
genes based on homology to the most highly constitutively expressed genes in the Clostridium 
beijerinckii genome179, hypothesizing that the SFB homologs performed similar functions and 
were expressed similarly. Each UTR also contained a bacterial RBS180; the last 36 bp of SFB 
promoter 4, containing the RBS, was used to drive translation of sfGFP in the catP/sfGFP operon 
(Figure 4.1b). We validated that all 5’ UTRs were capable of driving GFP expression in E. coli 
(Table 4.1), suggesting that these UTRs are sufficient to initiate transcription and translation in a 
broad range of bacteria. Putative SFB genetic parts are summarized in Table 4.1, and the MAGIC 
vectors for SFB (pSFB plasmids) constructed using these parts are summarized in Table 4.2. 
 
Design of MAGIC donor strains for optimized gene transfer into SFB.  
As in Chapter 3, we utilized an E. coli donor strain with a genomically integrated IncPα-
family RP4 conjugation system138 to conjugate genetic vectors into SFB in situ. Donor strain EcGT2 
(∆asd::mCherry-specR) was additionally engineered to be auxotrophic for the essential cell wall 
component diaminopimelic acid (DAP)139. Spectinomycin resistance and DAP auxotrophy provide 
simple selection and counter-selection for the donor strain, while the constitutively expressed, 




In general, restriction-methylation systems are barriers to horizontal gene transfer between 
species, as these systems recognize and cleave transferred DNA with foreign methylation 
patterns135, 181. We anticipated restriction-methylation encoded in the SFB genome to limit the transfer 
of MAGIC vectors from E. coli. To circumvent this potential problem, we expressed native SFB DNA 
methyltransferases in the E. coli donor to methylate MAGIC vectors in an SFB-like pattern prior to 
conjugation. We created two derivative strains of EcGT2, EcGT3 and EcGT4, each of which contains 
2 annotated SFB methyltransferases on a pSC101 origin plasmid (Figure 4.2a). In EcGT4, one of 
the methyltransferases belongs to a Type I restriction-modification system and was cloned with its 
associated specificity subunit into the plasmid182. The presence of additional methyltransferases in 
the E. coli donor strain resulted in slightly slower growth in vitro (Figure 4.2b). 
 
Preliminary studies of in situ gene delivery in SFB-monoassociated mice.  
With the help of our collaborators in Dr. Kenya Honda’s lab at RIKEN Center for Integrative 
Medical Sciences, we tested the MAGIC system for genetic engineering of SFB in situ using SFB-
monoassociated (SFB-mono) mice in a gnotobiotic facility. EcGT3 and EcGT4 strains carrying one 
of four pSFB MAGIC vectors were gavaged as a mix of 8 strains into young adult SFB-mono mice 
over 2 days (Figure 4.3a, groups A-C). In a separate gnotobiotic isolator (group D), mice were 
gavaged with EcGT3 and EcGT4 strains without MAGIC vectors as a control to examine the length 
of E. coli colonization in the SFB-mono mouse gut and serve as a negative control for flow cytometry. 
Fecal samples taken over time post-gavage were analyzed by microscopy of fecal smears and by 
flow cytometry of fecal bacteria to look for GFP+ SFB. The presence of E. coli in the gut over time 
was monitored by plating fecal contents in vitro and counting CFUs as well as by microscopy of fecal 
smears. Additional fecal samples were taken at each time point post-gavage and frozen for future 
analysis. Tissue samples and luminal contents were also collected from each mouse post-
euthanasia for further analysis. 
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 The EcGT3 and EcGT4 donors transiently colonized the GI tract of SFB-mono mice post-
oral gavage. In a separate preliminary experiment, mice gavaged with a single bolus of 10^9 E. coli 
cells had no detectable E. coli in their feces after 72 hours (data not shown). After being orally 
gavaged to SFB-mono mice as two boluses of 10^10 cells, the EcGT3 and EcGT4 donors transiently 
colonized the gut for at least 4 days but less than 7 days, being undetectable by plating and 
microscopy by 7 days (Figure 4.3b). Flow cytometry for SFB on day 4 showed the presence of GFP-
expressing, mCherry-negative bacteria in feces from the mice treated with MAGIC vector donors, 
but not the mice treated with donor controls or untreated mice (Figure 4.4a-b). As plating and 
microscopy showed that the feces was free of contaminating bacteria, the GFP+/mCherry- bacteria 
were likely to be GFP-expressing SFB that had received the pSFB vector. 
 The mice that received the pSFB vectors were given antibiotics in drinking water starting at 
day 4 or day 8 to select for pSFB recipients. Mice in groups A and B were given chloramphenicol to 
select for SFB with the pSFB genetic payload and neomycin to select against E. coli donors, while 
mice in group C were given only neomycin. Feces of group 1A mice were examined at day 7 and 8, 
after 3 and 4 days of antibiotic treatment, respectively. SFB filaments were present in feces on both 
days, although in lower numbers than before. Filaments on day 8 appeared fainter and shorter than 
those at day 7 (Figure 4.3b), suggesting that SFB were being selected against by chloramphenicol. 
Flow cytometry of fecal bacteria collected on day 8 showed no GFP+ SFB in groups A, B, or D 
(Figure 4.4c). This result indicates that GFP+ SFB did not maintain GFP expression 4 days after 
being detected, in the presence or absence of antibiotic selection for the payload. After antibiotic 






Preliminary study of in situ gene delivery in NSG mice.  
NSG mice colonized with SFB-mono mouse feces were used as a specific pathogen-free 
(SPF) animal testbed for genetically manipulating SFB within a conventional microbiome. NSG mice 
orally gavaged with feces from SFB-mono mice have higher titers of SFB (personal communication 
with Ivo Ivanov) than wild-type mice, potentially increasing the likelihood of detecting transconjugant 
SFB after MAGIC. We gavaged these mice with EcGT3 and EcGT4 donors harboring pSFB vectors 
(n = 4 mice) or with empty EcGT3/EcGT4 donors as a negative control (n=1) over three days (Figure 
4.5). We collected fecal samples over 6 days following the first gavage for FACS enrichment of GFP+ 
SFB and tissue samples at the end of the experiment. Mice were not treated with antibiotics, so any 
gene transfer into SFB would occur in the context of a native microbiome. 
 We attempted to isolate GFP-expressing SFB directly by FACS, following previously 
published protocols for FACS isolation of SFB from SFB-mono mouse feces183. The NycoPrep 
enrichment of SFB described by Farkas et al. failed to enrich SFB to sortable levels in the NSG 
mouse feces, so we omitted that step and sorted fecal bacteria directly extracted from feces, stained 
with SYTO40, and filtered through a cell strainer. However, we were unable to detect SFB based on 
SSC-W and SSC-A profiles, likely due to the low abundance of SFB compared with other gut 
bacteria. Fecal samples were frozen for future analysis. 
 
4.3. Discussion 
 In this chapter, we rationally curated the first set of genetic parts and selection markers for 
SFB and attempted pilot experiments to genetically engineer SFB in situ in gnotobiotic SFB-mono 
mice and in SPF NSG mice. The SFB-mono mouse experiment provided useful information on the 
survival of E. coli MAGIC donors in the guts of gnotobiotic mice and promising FACS data showing 
potential GFP-expressing SFB prior to antibiotic treatment. In the NSG mouse experiment, SFB 
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was not detectable by FACS among the high abundance of other bacteria in a conventional mouse 
microbiome, making it difficult to assess whether horizontal gene transfer into SFB occurred. These 
studies require additional follow-up work to confirm and replicate the observed results and to 
optimize protocols for genetically manipulating SFB in functional genetic studies. 
In the SFB-mono experiment, mice treated with E. coli donors of pSFB conjugative 
transposon plasmids appeared to have GFP-expressing, mCherry-negative bacteria in their feces 
4 days later, which were presumed, but not confirmed, to be genetically modified SFB. This 
experiment should be repeated, with FACS-enrichment for the presumed GFP+ SFB and 16S 
sequencing on these cells to verify that they were in fact SFB and not incorrectly gated E. coli. 
Microscopy on the FACS-enriched population would enable distinguishing between GFP+ SFB vs. 
E. coli, which have very different morphologies. Using a GFP+ negative control donor strain, rather 
than the mCherry+/GFP- empty donor strain, would also provide a more directly comparable GFP+ 
background in flow cytometry studies.  
The antibiotic selection protocol used in the pilot SFB-mono experiment requires additional 
optimization for future experiments. We performed antibiotic selection using chloramphenicol and 
neomycin to select for SFB carrying the genetic payload in one group of pSFB-treated mice (Group 
A, Figure 4.2a), but failed to see expansion of the GFP+ SFB population after antibiotics, only a 
decrease in the number and size of filaments (Figure 4.2b). We did not follow up on the effects of 
antibiotic treatment on the other groups, which were dosed on different schedules, nor on group A 
after day 8, when antibiotics were discontinued. PCR quantification of SFB prevalence in fecal 
samples collected throughout the experiment will elucidate whether some SFB survived the 
antibiotic regimen and expanded after antibiotic selection. If all SFB were killed, the chloramphenicol 
concentration we used may have been too high. We had previously validated that this level of 
chloramphenicol was sufficient to eliminate SFB from the gut (Figure 4.1c), but had not identified 
the minimum inhibitory concentration (MIC) of chloramphenicol on SFB. The MIC can be 
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determined by giving cohorts of SFB-harboring mice different dosages of chloramphenicol (or other 
antibiotics) and measuring SFB prevalence in feces by qPCR. In future iterations of the mouse 
experiment, selecting for payload-carrying SFB using the MIC of chloramphenicol may result in 
better retention of those SFB. Additionally, the co-administration of neomycin to kill off E. coli donor 
cells may not have been optimal. It is possible that administering chloramphenicol only or the two 
antibiotics in succession might have resulted in more effective selection for payload-containing SFB; 
further experiments testing different antibiotic dosing schedules are required. 
Optimization of the donor strain and donor dosage is also likely to influence the rate of HGT 
into SFB. We attempted to optimize donor strains EcGT3/4 for HGT into SFB by expressing SFB 
DNA methyltransferase systems in these strains. However, we have not yet confirmed that the 
presence of these additional methyltransferases actually results in new DNA methylation patterns 
in these cells, which can be done by single-molecule real-time (SMRT) sequencing184. It is also 
unclear to what extent the native E. coli methyltransferases present in EcGT3/4 inhibit HGT into 
SFB. If DNA methylation is a significant barrier to gene transfer, the methylation-free E. coli strain 
ER3413185 may serve as the basis for engineering an optimized donor strain harboring only SFB 
DNA methyltransferases. The timing and dosage of donor cells also needs to be further studied. In 
SFB-mono mice, the donor strain persisted for 4-7 days after being gavaged as 2 boluses of 10^10 
cells, but even at day 4, there were few donor cells present in the gut. The life cycle of SFB takes 
about 3 days, and it is unclear at what stage of its life cycle SFB is most receptive to HGT. The 
donor gavage schedule may need to be altered to maintain a high titer of donor cells for a longer 
time to facilitate HGT events. 
If the MAGIC platform can be optimized to enable efficient gene delivery and expression in 
SFB, it can enable functional genetic studies of SFB for the first time, without the need for in vitro 
cultivation. Introducing a random transposon and associated transposase (such as Himar) into SFB 
would allow for the generation of a transposon knockout library and screening for genes that are 
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involved in epithelial adhesion, life cycle control, and immune response stimulation. Novel genes 
(for example, genes from rat SFB) could be introduced into SFB to determine which genes are 
responsible for host specificity169. With genetic engineering tools available, the biology of SFB could 
be greatly elucidated by functional screens, and SFB could potentially be developed as a synthetic 
biological chassis for delivering molecules to the intestinal epithelium in therapeutic applications. 
 
4.4. Materials and methods 
Construction of pSFB vectors. Plasmids were constructed by isothermal assembly (ITA) using 
existing plasmid backbones (p15A), resistance markers (catP from pJIR750, E. coli beta-
lactamase), and Himar1 transposon and transposase sequences from pSAM-BT. Novel promoters 
identified from the SFB genome were ordered as a gBlock of 4 concatenated promoters (Integrated 
DNA Technologies) and subsequently PCR amplified and used in ITA reactions. PCR reactions 
were performed using Kapa Hifi PCR Master Mix (KAPA Biosystems).  ITA reactions were 
performed using the Hifi DNA Assembly kit (New England Biolabs). 
 
Construction of SFB methyltransferase plasmids. Five SFB DNA methylation systems 
(SFBM_0801 and SFBM_0802, SFBM_0805, SFBM_0018 and SFBM_0020, SFBM_1080, 
SFBM_0619) were inferred from the annotated SFB-mouse-Japan genome (NCBI accession 
number NC_015913). These methylation systems were amplified from SFB genomic DNA using 
the primers listed in Table 3, using Kapa Hifi PCR Master Mix. To make a plasmid containing all 5 
methylation systems, the 5 PCR products and a pSC101 vector backbone were mixed in equimolar 
ratios in an ITA reaction using the Hifi DNA Assembly kit (New England Biolabs). Among the 
reaction products, we did not produce the intended plasmid, but only plasmids containing at most 2 
out of 5 methylation systems, likely due to the large DNA fragment sizes and low GC content. 
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Plasmids pSFBMT1 and pSFBMT2 were confirmed by PCR and Sanger sequencing to contain 2 
methylation systems each and were transformed into E. coli strain EcGT2 to make strains EcGT3 
and EcGT4. 
 
Mouse care. Gnotobiotic mice were housed in germ-free isolators and fed a standard germ-free 
diet. NSG mice were purchased from Jackson Laboratories and raised in a SPF animal facility, 
until 2 days prior to gavage, when they were moved to sterile cages within a sterile laminar flow 
hood. NSG mice were fed a standard autoclaved diet. Female young adults (7-8 weeks old) were 
used for all experiments. When applicable, drinking water was supplemented with DAP (500μM), 
chloramphenicol (0.5 g/L), neomycin (1 g/L), and/or erythromycin (0.1 g/L). Water containing 
antibiotics was also supplemented with sterile filtered 1% sucrose to encourage water intake. 
Water was changed every 2 days to prevent antibiotic degradation. 
 
Culturing E. coli donor strains for gavage. EcGT3 and EcGT4 strains were grown in LB + DAP 
50μM + tet 15 μg/mL. EcGT3/EcGT4 strains harboring pSFB plasmids were grown in LB + DAP 
50μM + tet 15 μg/mL + carb 50 μg/mL. E. coli were grown in a 37C shaking incubator for 12-14 
hours from a frozen glycerol stock; 200 μL of the saturated overnight culture was diluted into 4 
mL of fresh media and grown at 37C with shaking for 6 hours. Cell density was quantified by 
OD600 using a Nanodrop. Cells were spun down at maximum speed on a tabletop centrifuge at 
room temperature and resuspended in PBS with 50μM DAP twice; 109 -1010 cells were then 
suspended in a final volume of 300 μL PBS with 50μM DAP for gavage. 
 
Analysis of SFB-mono fecal bacteria. Fecal samples collected from SFB-mono mice were 
analyzed by microscopy, plating, and flow cytometry. Fecal smears on microscope slides were 
Gram stained and imaged by bright field microscopy. Fecal pellets were weighed and 
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homogenized in 1 mL final volume of PBS per pellet, as described in Chapter 3. Bacterial extracts 
were plated on LB + 50 µM DAP or GAM + 50 µM DAP agar plates in dilutions to count E. coli 
CFUs and check for contamination. 
 To prepare bacteria for flow cytometry, bacterial extracts from 300 mg of feces were 
combined and diluted 1:10 in PBS and exposed to air for 30 minutes. The bacteria were then 
stained with 1.5 µL/mL SYTO40 (ThermoFisher) for 30 minutes protected from light and filtered 
through a 40 μm mesh strainer and analyzed on a BD FACSAria III or BD LSR Fortessa. Gating 
for GFP+ SFB was accomplished by gating out mCherry+ donor cells on a PE-A (yellow 
autofluorescence) vs. mCherry-A scatter plot and gating for SYTO40 stained cells on a PE-A vs. 
Pacific Blue-A scatter plot. The SYTO40 stained cells (presumably SFB) were then gated into 
GFP+ and GFP- groups on the GFP Alexa 488-A channel. 
 
FACS analysis of NSG mouse fecal bacteria. Fecal pellets were homogenized in 1 mL final 
volume of PBS per pellet, as described in Chapter 3, and bacterial extracts were combined by 
cage. Bacterial extracts were exposed to air for 30 minutes and then stained with 5 µM SYTO 40 
for 30 minutes, protected from light, and filtered through a 40 μm mesh strainer. The stained 
bacteria were diluted 1:10 and 1:50 in PBS and analyzed on a BD FACSAria II. SYTO40 stained 
cells were gated on the Pacific Blue fluorescence channel, and GFP (FITC channel) and SSC-W 
gates were set using bacteria from cage 2 (negative control) mice. The gate for GFP-expressing 
SFB was SYTO40+, high SSC-W, GFP+, mCherry-, but we were unable to detect these cells. 
 
16S qPCR for SFB in fecal samples. Metagenomic DNA was extracted from fecal bacteria 
samples using the MasterPure Gram Positive DNA purification kit. qPCR reactions were 
performed with primers 5′-GACGCTGAGGCATGAGAGCAT-3′ and 5′-
GACGGCACGGATTGTTATTCA-3′ for SFB, and 5′-ACTCCTACGGGAGGCAGCAGT-3′ and 5′-
ATTACCGCGGCTGCTGCG-3′ for Eubacteria (universal)183. qPCRs was performed using the 
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Kapa SYBR Fast qPCR Master Mix on a BioRad CFX96 Touch thermocycler. Reaction conditions 
were as follows: 3 minutes initial denaturation at 95C followed by 40 cycles of 3 second 
denaturation at 95C and 20 second annealing/amplification at 62C. A known SFB-containing fecal 





Experiments in gnotobiotic mice, microscopy, and FACS analysis were performed by our 
collaborators Seiko Narushima, Koji Atarashi, and Kenya Honda at RIKEN Center for Integrative 
Medical Sciences. Ivo Ivanov, Casandra Panea, and Carolyn Lee assisted with preliminary mouse 
experiments at Columbia. Plasmid pJIR750 was obtained from ATCC (#87015). Antibiotic icon in 
figure 4.1 made by mavadee from www.flaticon.com.   
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All experiments were performed in accordance with Columbia University Medical Center IACUC 
protocol #. All gnotobiotic mice experiments were performed in accordance with RIKEN Center for 




Table 4.1. SFB genetic parts. 5’ UTR sequences from SFB and C. perfringens have Shine-
Dalgarno sequences (putative RBSs) underlined. 
Promoter sequence Expression 
in E. coli 































































































































Table 4.3. Primers used to construct SFB methyltransferase vectors. Primers contain 5’ 
overhangs to allow for isothermal assembly. 

































































Figure 4.1. Implementation of MAGIC to genetically engineer Segmented Filamentous 
Bacteria (SFB). (a) Schematic of in situ horizontal transfer of selectable genetic payloads into 
SFB. (b) Plasmid map of pSFB vectors containing a payload with the catP chloramphenicol 
resistance gene and a GFP gene on a Himar transposon. The associated Himar1C9 hyperactive 
transposase is delivered with the transposon to stably integrate the payload into the SFB genome. 
Promoter and RBS sequences were obtained from the SFB genome and from a C. perfringens 
plasmid. (c) Measurement of SFB antibiotic susceptibility in conventional B6 mice. Cages of 2 
mice each were treated with 4 days of chloramphenicol, erythromycin, or no antibiotic in drinking 
water, then switched to neomycin in drinking water. SFB prevalence in fecal samples collected 




Figure 4.2. Characterization of SFB-optimized donor E. coli strains. (a) Donor strains EcGT3 
and EcGT4 were generated from parent strain EcGT2 with the addition of SFB DNA 
methyltransferase systems on a pSC101 plasmid. (b) EcGT3 and EcGT4 strains grow slightly 
slower than the EcGT2 strain, both with and without an additional pSFB1 plasmid, and reach a 
lower concentration at saturation. OD600 was measured during growth at 37C on a BioTek plate 







Figure 4.3. Implementation of MAGIC to genetically engineer SFB in SFB-monoassociated 
mice. (a) Experimental setup. Groups A-C were each housed in their own cage within the same 
gnotobiotic isolator, while Group D was housed in a cage in a separate isolator. Mice were 
gavaged with 2 boluses of 10^10 E. coli donor cells mixed in equal proportions. The colored bars 
on the timeline show the duration of antibiotic treatment or DAP supplementation in drinking water. 
Fecal samples were collected over time for microscopy, FACS analysis, and plating to quantify E. 
coli presence and identify contaminants. Tissue samples were collected at the end of the 
experiment. (b) Micrographs of fecal smears over time. E. coli (green arrows) were visible in 
samples collected up to day 4, but not at day 7 or after. Group A (treated with antibiotics from day 
4 to day 8) showed decreased numbers of filaments and smaller, fainter filaments at days 7 and 
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Figure 4.4. Flow cytometric analysis of fecal bacteria from SFB-monoassociated mice after 
gavage with MAGIC donors. (a) Gates used to identify GFP+ SFB. mCherry+ donor E. coli (P2, 
magenta) were gated out on the basis of having mCherry fluorescence greater than PE 
autofluorescence. SFB stained with SYTO40 (P6, red) were gated on the basis of having blue 
fluorescence greater than PE autofluorescence. P7 (green) represents the population of GFP+ 
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SFB. (b) Flow cytometry of fecal bacteria on day 4 of the experiment. Mice from Isolator 1 had a 
small fraction of GFP+ SFB present in feces, while mice in isolator 2 (gavaged with the empty 
donor strains) and untreated mice did not. (c) Flow cytometry of fecal bacteria on day 8 of the 
experiment. Mice in Group A had undergone 4 days of antibiotic treatment to select for 
chloramphenicol-resistant SFB, while Groups B and D had not undergone antibiotic treatment. In 






Figure 4.5. Implementation of MAGIC to engineer SFB in specific pathogen free (SPF) NSG 
mice harboring SFB. Mice were gavaged with 3 boluses of 10^9 donor cells (mixed in equal 
proportions) over 3 days. Fecal samples were collected over time for FACS to enrich for GFP+ 




Conclusions and Future Perspectives 
As the field of microbiome research progresses from characterization of microbiomes 
using -omics approaches to experimentally testing hypotheses about microbial ecology and host-
microbiome interactions, tools for making functional genetic modifications to the microbial 
community will be invaluable. The Cas-Transposon and MAGIC platforms presented here aim to 
address the need for technologies that enable genome alterations across a wide phylogenetic 
range, including microbes that are uncultivable or not currently genetically tractable, because 
many of them are involved in important physiological processes. The Cas-Transposon system 
enables host-independent targeted genome editing using Himar-dCas9 (HdCas9) fusion 
transposases as an alternative to CRISPR-Cas genome editing. Because the Himar transposase 
operates independently of host factors, it can efficiently insert larger pieces of DNA than 
homologous recombination machinery, potentially enabling insertion of operon-sized (multi-kb) 
pieces of DNA into a target locus. In Chapter 2, we demonstrated that HdCas9 transposition 
activity is targeted to a gRNA-defined locus in both cell-free in vitro reactions and in plasmid-
based assays in E. coli.  The MAGIC platform complements Cas-Transposons, serving as a 
delivery tool to introduce DNA into a wide range of organisms within the gut microbiome without 
the need for cultivation. Using MAGIC, we showed that diverse bacteria spanning multiple phyla 
were amenable to genetic manipulation by in situ conjugation, expanding the range of gut bacteria 
that can potentially be used as targets or chasses for insertion of synthetic DNA (Chapter 3). 
Furthermore, native gut bacteria could be engineered by in vitro conjugation and then deployed 
back into their host animal to recolonize the environment and promote long-term infiltration of 
engineered gene constructs into the metagenome. We piloted the use of MAGIC to genetically 
modify Segmented Filamentous Bacteria, an uncultivable gut commensal, with promising 




Optimization of platform technologies 
At present, both technologies described in this work remain in an early phase of 
development and can be optimized further. In the case of the Cas-Transposon system, we 
demonstrated in vitro and in vivo gRNA-targeted transpositions into a plasmid using the HdCas9 
protein, but targeting transposition to a single-copy genomic locus within a genome is a greater 
challenge, requiring high efficiency of transposition at the target locus and low efficiency at all off-
target sites. We propose several approaches to overcome this challenge. First, protein 
engineering may produce HdCas9 proteins with both higher transposition specificity and 
efficiency; a directed evolution approach might be used to evolve transposases that insert 
preferentially at gRNA-targeted sites. Rational protein design, such as making alterations to the 
allosteric inhibition domain of the Himar protein while also mutating the dimerization interface, 
could achieve the same effect by increasing the efficiency of transposition when transposases 
are stably bound to the target locus, but decreasing the probability that transposases dimerize at 
low local concentrations elsewhere. Further optimization of delivery/expression of the system 
components (protein, gRNA, and transposon DNA) into cells is also likely necessary for in vivo 
function. We can also engineer different varieties of targeted transposases, containing different 
transposase domains and DNA-binding catalytically dead nucleases189, 190, with different targeting 
behaviors, which may be useful in organisms with different genomic distributions of insertion sites 
and protospacer adjacent motifs.  
Future improvements to the MAGIC system would address the need for targeted gene 
delivery and actuation of engineered functions in specific microbes or subsets of microbes. The 
specificity of the MAGIC system can be tailored to particular microbes in several ways. First, 
MAGIC vectors can be engineered with specific or broad host-range origins of replication and with 
regulatory elements that are selectively recognized by certain microbes143, 191.   Conjugation into 
selected strains can also be enhanced by using a donor strain that localizes in a specific area of 
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the gut, longitudinally (proximal vs. distal) or radially (in the lumen vs. attached to the mucosa), to 
increase the likelihood of conjugation into the more abundant microbes at that site192. Horizontal 
gene transfer (HGT) into targeted microbes can also be enhanced by designing vectors to avoid 
motifs that are recognized by the recipient’s defense mechanisms against foreign DNA, such as 
restriction-modification systems135 and CRISPR/Cas systems91, or by expressing recipient DNA 
methyltransferases in the donor strain, as we did for SFB in Chapter 4. As we discover and 
characterize new anti-DNA defense systems in bacteria193, strategies to enhance HGT by 
avoiding these systems may additionally come into play.  
Greater temporal control of genetic payload persistence in the gut can be achieved by 
optimizing the lifetime of the donor strain. As we observed in Chapter 3, a single gavage of a lab-
adapted donor strain resulted in a transient (<72 hour) perturbation of the mouse gut 
metagenome, while a single gavage of an engineered donor strain resulted in stable 
recolonization and engraftment of the payload genes into the gut metagenome. By altering the 
donor strain (gut adapted vs. non-adapted) and gavage conditions (single vs. multiple doses, 
number of bacteria per dose) we may be able to fine-tune the concentration of donor cells and 
temporal duration of the metagenomic perturbation. To control for the number of cells surviving 
passage through the stomach and entering the intestines, it may also be useful to encapsulate 
the donor bacteria in a protective coating during delivery through the stomach; this encapsulation 
strategy may reduce variations between individual mice in the level of HGT and metagenomic 
perturbation. 
  
Future research directions 
The technologies described here enable multiple types of studies of naturally occurring 
microbiomes. The Cas-Transposon and MAGIC technologies can be combined, with MAGIC 
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serving as a delivery platform for Cas-Transposon components, to enable engraftment of a novel 
gene function into a microbiome and/or removal of an existing gene from the metagenome without 
altering the microbial composition of the community. Genes within the gut microbiome that may 
be candidates for functional manipulation in host-microbiome interaction studies include bile salt 
metabolism genes, which encode microbial proteins that alter the balance of bile acids present in 
the body and modulate hormonal signaling pathways that use bile acids as signal molecules194. 
The abundance of particular bile salt metabolism genes within mammalian microbiomes has been 
shown to affect resistance to pathogen invasion and host metabolism40, 195, making the population 
of bile salt hydrolase and dehydrogenase genes a potential target for gene therapy aimed at 
improving host health. Other microbial genetic functions that could be deleted to improve host 
health include genes for antibiotic resistance and virulence factors in pathogens, as well as genes 
in commensal bacteria that are involved in the production of harmful compounds such as 
trimethylamine, which promotes atherosclerosis and has been linked to colorectal cancer25, 196.  
In the setting of other microbiomes, in situ genetic engineering may be utilized for 
bioremediation applications. For example, soil and marine environments are frequently 
contaminated with pollutants such as plastic particles or toxins from industrial/agricultural activity. 
It would be useful to introduce novel gene pathways into the bacteria that occupy these 
environments for sensing and metabolism of pollutants, although safety and biocontainment of 
genes delivered into open environments would be paramount concerns. Antibiotic resistance 
genes are also commonly distributed among bacteria in agricultural settings, as a result of 
antibiotic use in farm animals, and these resistant bacteria pose health hazards to both humans 
and animals. Removal of antibiotic resistance genes from these environmental bacteria would be 
another useful bioremediation application.  
At present, engraftment of new genetic functions is more feasible than removal of a gene 
from a microbial population. We observed in Chapter 3 that up to 5% of mouse gut bacteria could 
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be identified as transconjugants of our libraries of conjugative vectors, showing that new genes 
can be disseminated and expressed from a significant fraction of the native microbiome. However, 
removing a gene from a population of cells is more difficult, since the probability of on-target 
homologous recombination (if using CRISPR-Cas9 genome editing) or transposition (if using Cas-
Transposons) in each cell is small, preserving the gene function in most cells. To improve the 
efficacy of removing a gene from a microbiome, the Cas-Transposon system could be adapted to 
serve as a gene drive, in which genes for the targeted transposase and gRNAs complementing 
the unwanted gene are propagated through a population on a conjugative transposon. In such a 
system, targeted gene knockout events are not limited only to microbes that directly receive the 
Cas-Transposon system, but also recipients of secondary conjugative transfers (and beyond). 
Mariner transposases such as Himar operate in a cut-and-paste fashion, but leave a 2-nucleotide 
duplication upon insertion and excision; if Himar-dCas9 were to be used as a gene drive, an on-
target transposition event followed by excision and conjugation of the transposon would result in 
a frameshift mutation of the target gene. 
MAGIC can also be used to characterize HGT pathways within a microbiome in detail. In 
our studies in Chapter 3, we identified the recipient ranges for several vectors by looking for 
expression of one or more genetic markers present on the transferred vector. However, these 
recipients represent only a subset of microbes that actually received the vector. It is likely that 
some microbes received a vector via conjugation but did not express any of the genetic markers, 
due to either incompatibility of protein function or transcriptional/translational regulatory elements. 
For example, GFP requires oxygen to fold and may not be expressed well in gut anaerobes that 
are particularly sensitive to oxygen, while antibiotic resistance proteins may not fold properly, bind 
their target, or be transported to the correct cellular location in some species, impeding their 
function. To understand HGT, it is necessary to differentiate between microbes that received a 
genetic vector but did not express the genes on the vector and those that were non-recipients. 
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Using a DNA detection system, such as fluorescence in situ hybridization (FISH), in conjunction 
with MAGIC, it would be possible to detect bacteria that were successful recipients of a given 
vector, regardless of gene expression. Correlating recipients identified by gene expression versus 
by direct DNA detection would yield information about the ability of each recipient to express the 
transferred genes. We could also correlate the relative abundance of each transconjugant 
containing transferred DNA with its abundance in the whole population to determine which 
bacteria are more likely to receive the vector. Bacteria resistant to conjugation may have defense 
systems that recognize and eliminate the vector, contain native plasmids which are incompatible 
with the vector, or be unable to produce necessary replication/integration factors. Further analysis 
of transconjugants using the MAGIC approach will elucidate the landscape of HGT within naturally 
occurring microbiomes. 
Results in Chapter 3 also highlight the possibility of developing engineered personalized 
probiotics tailored to individual hosts. Because every individual has their own stable microbiome, 
exogenous bacteria such as commercial probiotics do not readily infiltrate the microbiome and 
are only transiently present and active after consumption. To confer longer-lasting effects on the 
microbiome, native strains from the host’s microbiome could be engineered with novel genetic 
functions and then redeployed into the gut. This finding can be generalized for other hosts, 
potentially including humans; native gut bacteria from individuals can be engineered with useful 
functions to serve as host-adapted probiotics that persist for a longer period of time after 
consumption. New functions that may be interesting to confer to native bacteria include sensing 
systems for small molecules, metabolism genes to manipulate energy harvest within the gut, and 
pathways for the production of beneficial small molecules. However, these bacteria would also be 
need to engineered with safety mechanisms to prevent the indefinite persistence of the 
engineered functions once they are no longer desired, and to prevent the spread of the genes 




Biocontainment of synthetic DNA in microbial communities 
The potential deployment of synthetic gene constructs by in situ conjugation into open 
environments necessitates the discussion of biocontainment strategies. In Chapter 3, we 
observed that genes transferred into native gut bacteria could have different lengths of 
persistence in the transconjugant population without selection, depending on the gene function 
and the payload design. A strain of E. fergusonii containing a replicative vector with beta-
lactamase and GFP genes lost the GFP gene from most of the population within several days, 
but 100% of the population remained beta-lactam resistant during that time. When beta-lactamase 
and GFP genes were introduced into E. fergusonii as a single operon on an integrative 
transposon, the two genes persisted together in 100% of the population, even as the 
chloramphenicol resistance gene on the vector backbone was lost over time. The spread and 
longevity of antibiotic resistance genes in microbial communities is a global public health hazard, 
as it renders antibiotics ineffective in the treatment of disease. Our studies in Chapter 3 highlight 
the potential danger of letting a synthetic gene construct loose in the wild, as that gene construct 
may persist and propagate indefinitely. 
Several biocontainment strategies may be employed to limit the conjugative spread of 
synthetic DNA. The first is to utilize narrow host range vectors for gene delivery, such as plasmids 
that require specific replication factors that are not widely distributed (e.g., R6K origin of 
replication, which needs the pir protein to replicate). Bacteriophages, which only infect specific 
hosts, are another way to deliver DNA into a narrow host range of recipients. Genetic payloads 
can also be linked to a toxin-antitoxin system, so that the payload is always co-expressed with a 
toxin and leads to cell death in any off-target transconjugants that do not contain the antitoxin 
gene. The toxin gene could be built into the same operon as the payload, or encoded into a 
payload gene in a different reading frame. Finally, a Cas-Transposon-based gene drive against 
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an unwanted genetic payload could be used to eliminate that payload from a given population. 
Development of novel biocontainment strategies will improve our control over HGT of engineered 




 With continued advances in the field of synthetic biology, the array of genetic engineering 
tools available to biologists will enable increasingly fine-tunable and programmable modifications 
of a wider range of organisms. The technologies presented in this thesis are two of among many 
developments ongoing in this field, and can be used synergistically with many other genome 
editing and gene delivery approaches. Using novel genetic engineering techniques, we will be 
able to better understand the mechanisms driving ecology in natural microbiomes, through 
functional genetic studies of complex populations, and also be able to engineer microbiomes in 
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Appendix 3: Technical notes on MAGIC experiments on mice 
 We performed MAGIC to alter the gut microbiota of mice over several independent 
experiments, which took place over 3 years and in 2 different mouse facilities, using multiple 
cohorts of mice. Here, we describe some technical considerations that are likely to affect the 
efficacy of in situ conjugation and gene expression in transconjugants, which may explain some 
of the variations seen between mice and between experiments. 
1. Facilities: Experiments in Figures 3.2 and 3.3 and Suppl. Figures S3.9, S3.10, S3.11, 
S3.14, and S3.15 were performed in 2016-2017 in the Hammer Health Sciences Center 
(HHSC) mouse facility, which did not have an air shower at the entrance and where mice 
were kept in cages with individual food racks and water bottles. Experiments in Suppl. 
Figure S3.8 were performed in 2018 in the Irving Center for Cancer Research (ICRC) 
mouse facility, which had an air shower at every entrance and where mice were provided 
water from a central source (but food racks were placed in individual cages). The highest 
proportions of transconjugants and most diverse transconjugants were observed in 
experiments performed in HHSC, although we did not control for the starting microbiomes 
of the mouse cohorts involved. In conjugations of vector library pGT-L3 in each facility 
(Figure 3.2, Suppl. Figures S3.8 and S3.10) the proportion of transconjugants was similar, 
but the diversity of transconjugants was lower in the ICRC experiments.  
2. Mice: For all experiments, we used conventionally raised C57BL/6 female mice from 
Taconic Biosciences or Charles River Laboratories. The mice were purchased at 6 weeks 
of age. Gavage experiments were performed when the mice were 8-10 weeks old. Mice 
were randomly assigned to cages of 3-4 each and co-housed for at least 1 week before 
the gavage to equilibrate their microbiomes, and then randomly allocated into treatment 
groups prior to gavage. We thus assumed that the starting microbiome of each mouse 
used in a single experiment was relatively similar, across treatment groups. We observed 
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similar phylogeny and diversity of transconjugants between mice from the two vendors, 
despite quite different starting microbiomes. (Taconic: Figure 3.2, Suppl. Figure S3.9. 
Charles River: Suppl. Figures S3.8, S3.10.) We did not test other strains, ages, or sexes 
of mice, which may have different microbiomes, nor did we control for the starting 
microbiomes of the mice across different experiments.  
3. Donor strain:  
a. For all in situ conjugation experiments, we used EcGT2 as the donor strain; it 
remains unclear how other donor strains would perform in conjugation efficiency 
and ability to survive the gut.  
b. In all experiments, the donor strain was grown to saturation from a glycerol stock, 
and then rediluted and grown to saturation again at 37C. Donor strains in different 
growth phases (exponential phase, for example) were not tested and may have 
different survival and conjugation rates in the gut environment.  
c. To wash donor cells for gavage, cells were pelleted and resuspended 2x in PBS. 
10^9 washed donor cells, quantified by OD600 and in equal ratios for each vector 
in the vector library, were diluted into 300 uL of PBS for gavage. We kept 3-4 mice 
in a cage for each treatment group and combined n+1 300 uL doses of donor strain 
in a syringe. The same syringe was used to gavage slightly more than 300 uL of 
donor strain per mouse, and the bulb-tipped needle was not switched between 
mice in each treatment group.  
d. Although EcGT2 is auxotrophic for DAP, we did not add DAP to the PBS during 
gavage, as DAP is produced by other gut bacteria and is present in non-limiting 
concentrations in a conventional gut microbiome. We do not expect that adding 
DAP to the gavage media would affect EcGT2 growth in situ, but altering the 
gavage media in other ways may promote donor survival and HGT. 
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4. Timing of experiments: Mice have circadian rhythms and the gut bacteria are likely to 
fluctuate based on the time of day; it is possible that the bacteria are more amenable to 
HGT at some times of day rather than others. We started all of the experiments with time 
0 feces collection and gavage at 2-3 AM, followed by the 6 hour time point of fecal 
collection at 9 AM, as we were constrained by the logistics of booking the FACS machine 
in the core facility. 
5. Preparation of fecal samples:  
a. We tested two conditions for storage of fecal samples between the time of 
collection and downstream analysis by FACS or antibiotic plating, which was 
usually several hours later the same day: (1) Fecal samples were collected in 
microcentrifuge tubes and put on ice in the 4C room, aerobically, and (2) Fecal 
samples were collected in microcentrifuge tubes and put into an anaerobic 
chamber at ambient temperature (25-30C). Fecal samples kept anaerobically at 
ambient temperature contained far more viable transconjugants upon antibiotic 
selection than the fecal samples on ice, likely because the more oxygen and 
temperature sensitive species died under condition (1). 
b. To improve efficiency of bacterial extraction from feces, we found that collecting 3 
sets of fecal samples (or separating the fecal collection into 3 tubes) was useful. 
One set was immediately put into anaerobic conditions for downstream extraction 
in anaerobic conditions, followed by antibiotic selection. One set was frozen at -
80C for future use/analysis. One set was extracted with aerobic PBS aerobically 
for FACS analysis, which was much faster than doing the extraction in an 
anaerobic chamber, and provided the advantage of exposing the bacteria to 
oxygen to allow GFP to fold. 
